EDWARD M. MESSING, MD, FACS

EDWARD M. MESSING, MD, FACS

Edward M. Messing, MD is Professor of Urology and Oncology at the University of Rochester. Prior to this, he was the Winfield W. Scott Professor and Chairman of the Department of Urology at the University of Rochester School of Medicine and Dentistry from 1995–2018, and the Deputy Director of the James P. Wilmot Cancer Center at the University of Rochester from 1996-1998.

Dr. Messing received his degree from New York University in 1972, did his surgery training at NYU-Bellevue Hospital in New York 1972-1974,

and his Urology Residency at Stanford University 1974-1978. After 2 years on the faculty at Tulane University, he completed a fellowship in Urologic Oncology at UCLA in 1982. He was on the faculty of the Division of Urology at the University of Wisconsin from 1982-1995, being Director of their Urologic Oncology Program for the last 10 years.

Dr. Messing is a renowned expert on the diagnosis, prevention and treatment of cancers of the bladder, prostate, and kidney. He has conducted the largest screening study for bladder cancer in a general population and carries on extensive research in the basic biology of these cancers. He has been the principal investigator on numerous clinical studies for the detection, prevention and treatment of them several of which have changed the standard care for patients with these diseases.

Dr. Messing has served as an Examiner on the American Board of Urology and AUA Joint Examining Committee and served on the American Urological Association (AUA) Guidelines Panel on the Evaluation of Hematuria. Dr. Messing also held a leadership position on the Renal Cancer Subcommittee of the GU Committee of the Southwest Oncology Group (SWOG) and was formerly co-chair of the GU Committee of the Eastern Cooperative Oncology Group (ECOG). He has been President of the Society of Urologic Oncology and of the Northeastern Section of the AUA. He received the Ramon Guiteras Award in 2018, a Presidential Citation in 2013, the SUO Medal in 2016, and the SUO Distinguished Service Award in 2020. He has been a member of the AUA since 1984.

UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY DEPARTMENT OF UROLOGY

Curriculum Vitae

EDWARD M. MESSING, M.D. PERSONAL DATA Office Address: University of Rochester 601 Elmwood Ave. Box 656 Rochester, NY 14642 Phone: (585) 275-3345 Fax: (585) 442-8350 Birth Date and Place February 5, 1947 Brooklyn, New York Marital Status: Married EDUCATION College: 1964-1968 – B.A. - Biology University of Chicago, Chicago, Illinois Medical School: 1968-1972 - M.D. New York University, New York, New York Internship: 1972-1973 - Department of Surgery New York University - Bellevue Medical Center, New York, New York Residency: 1973-1974 - Surgical Residency New York University - Bellevue Medical Center, New York, New York 1974-1978 - Urology Residency Division of Urology, Stanford University, Stanford, California 1977-1978 - Chief Resident Division of Urology, Stanford University, Stanford, California

Edward M. Messing, M.D. -2- Curriculum Vitae

Military Service: 1978-1980 - Surgeon United States Public Health Service Fellowship: 1980-1982 - Tumor Immunology and Urologic Oncology Departments of Microbiology and Immunology and Division of Urology, UCLA School of Medicine, Los

Angeles, California BOARD CERTIFICATION The American Board of Urology LICENSURE State of California - G-27554 State of Wisconsin - 24996 State of New York - 118265 POSITIONS HELD January 2018 – present - Professor of Urology/Professor of Oncology and Pathology University of Rochester School of Medicine and Dentistry Rochester, New York July 1995 – December 2017 - Winfield W. Scott Professor and Chairman Department of Urology Professor of Oncology University of Rochester School of Medicine and Dentistry Rochester, New York January 1998 – December 2007 - Deputy Director, James P. Wilmot Cancer Center University of Rochester School of Medicine and Dentistry Rochester, New York September 1996 - January 1998 - Interim Director, Cancer Center University of Rochester School of Medicine and Dentistry Rochester, New York July 1992-July 1995 - Professor, Surgery/Human Oncology University of Wisconsin Medical School Madison, Wisconsin June 1989-July 1995 - Chief, Urologic Oncology Division of Urology Department of Surgery University of Wisconsin School of Medicine June 1987-June 1992 - Associate Professor, Surgery/Human Oncology University of Wisconsin School of Medicine Madison, Wisconsin


January 1987-July 1995 - Leader, Urologic Cancer Clinical and Research Program University of Wisconsin School of Medicine and Wisconsin Comprehensive Cancer Center

Madison, Wisconsin August 1982-July 1995 - Consultant William S. Middleton Veteran's Administration Hospital Madison, Wisconsin August 1982-June 1987 - Assistant Professor, Surgery/Human Oncology University of Wisconsin School of Medicine Madison, Wisconsin 1980-1982 - Adjunct Assistant Professor, Surgery/Urology NIH Supported Post-Doctoral Fellow in Immunology UCLA School of Medicine Los Angeles, California 1978-1980 - Clinical Assistant Professor of Urology Tulane University School of Medicine New Orleans, Louisiana 1978-1980 - Chief, Division of Urology U.S. Public Health Hospital New Orleans, Louisiana HONORS AND AWARDS Phi Beta Kappa University of Chicago 1968 Alpha Omega Alpha New York University School of Medicine 1972

The Samuel Soifer Memorial Award for Outstanding Work in Urology New York University School of Medicine 1972

Second Prize for Case Reports (Renal Arteriovenous Fistulas)

Northern California Urology Residents Seminar Davis, California December 1975

First Prize for Clinical Research and the Bill Smart Award (University of California) for best clinical paper (Interstitial Cystitis)

Northern California Urology Residents Seminar Stanford, California December 1977 Junior Faculty Clinical Fellow

American Cancer Society July 84 through June 1986


Sigma Xi The Scientific Research Society - 1985 Fellow American College of Surgeons - 1986 CaP Cure Award - 1999 - Best Clinical Research on Prostate Cancer The Davey Memorial Award - James P. Wilmot Cancer Center – 2009 2010 Best of Posters Award – AUA – 2010 Annual Meeting 2012 Best of Posters Award – AUA – 2012 Annual Meeting 2013 - Recipient of the 2013 AUA Presidential Citation Award 2013 Best of Posters Award – AUA – 2013 Annual Meeting 2016 – SUO Medal Recipient 2016 – George E. Slotkin SUO Lecturer – Northeast Section AUA 2018 - Robert S. Davis Teaching Award – URMC Urology Dept., Graduation 2018 2018 - Ramon Guiteras Award - AUA – 2018 Annual Meeting 2020 - SUO Distinguished Service Award - presented at AUA 2020 Annual Meeting PROFESSIONAL SOCIETIES American Association of Genitourinary Surgeons American Association for the Advancement of Science American Association for Cancer Research American College of Surgeons (Fellow) American Society of Clinical Oncology American Urological Association Association for Academic Surgery New York Academy of Science Society of Basic Urological Research New York Urological Society Society of Surgical Oncology Society of University Urologists Society of Urological Oncology American Association of Genitourinary Surgeons (Fellow) SOCIETIES - OFFICER Interstitial Cystitis Association - Scientific Advisor -1986 - present Society of Urologic Oncology - At Large Officer -1988 - 1989 Society of Basic Urological Research - At Large Officer- 1990 - present Wisconsin Urological Society - President 1991 - 1992 NE American Urological Association - Board of Directors – 2002 – present NE American Urological Association - Secretary – 2006; President-elect – 2009 – 2010; President Sept 2010 – October 2011; Past President - October 2011 – Sept 2012 Society of Urologic Oncology – President-elect 2009; President 2009 – 2012, Past President 2012 - 2015


COMMITTEES - NATIONAL AND INTERNATIONAL Society of Urologic Oncology - Subcommittee on Staging, 1991 – present

American Board of Urology/American Urological Association Joint Examining Committee, 1991 - 1993 Member, Bladder Health Council Subcommittee for Bladder Cancer - American Urological Association/American Foundation for Urologic Diseases, 1991 - present

NCI PDQ Screening and Prevention Editorial Board/Screening for Bladder Cancer - Special Advisor, 1997 - present International Committee on Superficial Bladder Cancer - Member of the Biomarker Task Force, 2001 - present NIDDK - Bladder Research Executive Committee; Head - Bladder Cancer Research NCI – Bladder Renal PDQ – Co-leader – Prevention and Detection Subcommittee American Urological Association Guidelines Panel on the Evaluation of Hematuria, 2009 - present

COOPERATIVE GROUP Eastern Cooperative Oncology Group Co-Chairman - GU Committee 1989 - 1998 Southwest Cooperative Oncology Group (SWOG) – 2001 - present GU Committee - Steering Committee Head – Local Renal Cancer subcommittee (2003 – present) UNIVERSITY OF ROCHESTER MEDICAL CENTER and COMMUNITY COMMITTEES Medical School Advisory Council

Informal Executive Committee URMFG Advisory Committee Council of Clinical Chairs Medical Staff Committee - Clinical Chairs/Chiefs James P. Wilmot Cancer Center - Executive Committee URMC Executive Committee

Perioperative Services Committee


Cooperative Group Studies

National Cancer Institute - ECOG - EST 3886 "Randomized Phase III Trial of Radical Prostatectomy plus Hormonal Therapy versus Radical Prostatectomy and Expectant Management in Patients with Advanced Regional (Pathologic Stages D1) Adenocarcinoma of the Prostate

Principal Investigator: E. Messing, M.D. National Cancer Institute - INT 006, EST 9887

"Treatment of Pathologic Stage C Carcinoma of the Prostate with Adjuvant Radiotherapy" Principal Investigator: I. M. Thompson, Jr., M.D. ECOG Coordinator: E. Messing, M.D. National Cancer Institute - INT 89-0001, ESTC 0490

"Pilot Trial of Difluormethylornithine (DFMO) in Patients with Superficial Bladder Cancer" Principal Investigator: C. L. Loprinzi, M.D. ECOG Coordinator: E. Messing, M.D.

Southwest Oncology Group (SWOG) – S0337 A phase III blinded study of immediate post-TURBT instillation of gemcitabine versus saline in patients with newly diagnosed or occasionally recurring grade I/II superficial bladder cancer. Principal Investigator: Edward Messing

ACTIVE and RECENT RESEARCH SUPPORT

NIH, U01 DK-065255-03 Title: Interstitial Cystitis Clinical Research Network Role: PI - Robert Mayer – Co-PI, Edward Messing Dates of Award: 9/1/03 – 2/28/08 Total Award: $1,361,598

NIH/R01 CA091763 Title: Robot-Assisted Platform for Intratumoral Delivery Role: Co-PI, Yan Yu - PI Dates of Award: 9/1/03 – 8/31/08 Total Award: $2,521,553 NIH/ N01CN35153

Title: Phase 1 and 2 Clinical Trials of Cancer Chemopreventive Agents and Phase II Study of Isoflavone PTI (Genistein) in Patients with Bladder Cancer (subcontract from University of Wisconsin)

Role: PI: Howard Bailey, MD Co-investigator: Edward Messing Dates of Award: 9/30/03 – 9/29/08 Total Award: $117,057 Photocure ASA Title: “A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection of Papillary Bladder Cancer and the Early Recurrence Rate in Patients with Bladder Cancer” Role: Principal Investigator Dates of Award: 8/30/04-10/1/08 Total Award: $40,405


Novadaq - Edward Messing (PI) Title: “Use of near infrared fluorescence in urologic disease” Dates of Award: 12/05 – 12/08 Total Award: $272,433 NIH/U01CA084986 (Johns Hopkins subcontract) Title: The Detection of Bladder Cancer by Microsatellite Analysis (MSA) of Urinary Sediment: Multi-institutional Study Role: PI: Edward Messing Dates of Award: 8/1/04 – 8/31/09 Total Award: $27,431 N01-CN-25000-39 Title: “Phase I and Clinical Trials of Cancer Chemopreventive Agents” Role: Howard Bailey (PI) Dates of Award: 3/1/03 – 9/29/09 R21CA131603 (NIH) Title: “A New Class of Mechanistic Risk Prediction Models for Cancer Treatment Outcomes” Role: Li-Shan Huang (PI) E. Messing Co-PI Dates of Award: 12/1/07-11/30/09 Total Award: $125,000 Photocure Title: “An Open, Non-Interventional, Retrospective, Comparative, Multicenter Follow-up Study in Patients Included in the Previously Completed Clinical Study PC B305/04, to Assess a Longer- Term Recurrence Rates in Patients After Hexvix Fluorescence Cystoscopy/TURB or White Light Cystoscopy/TURB” Role: Principal Investigator Dates of Award: 5/17/10-8/27/10 Total Award: $9,496

National Institutes of Health R25CA114101 Title: “Prospective Study of Dietary Habits and Bladder Cancer Recurrence” Role: Li Tang (PI) Co-Investigator – E. Messing Dates of Award: 9/1/09-8/31/11

Total Award: $3,532 R01 AG029804 (NIH) Deborah Rubens (PI)

Title: “3-D Prostate Cancer Imaging Based on “Crawling Wave” Excitation Dates of Award: 9/1/07-4/30/11 Total award: $573,796

2P50CA091846-06(S2) Title: “Screening for Bladder Cancer” Role: Colin Dinney (PI) Dates of Award: 9/01/06-8/31/12 Total Award: Subcontract/MD Anderson $79,763 National Institutes of Health

Title: “Stromal androgen receptors mediate human prostate cancer progression” Role: William Ricke (PI); Co-PI – E. Messing

Dates of Award: 9/28/07-7/31/12


Department of Defense W81XWH-08-1-0078 Title: “Functional Mechanism and Clinical Correlation of TAP/Sec14 L2 in Prostate Cancer” Role: ShuYuan Yeh (PI); Co-Investigator – E. Messing Dates of Award: 3/1/08-2/28/12 (1 year no cost extension) Total Award: $375,000

NIH / N01CN35153

Title: “Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol and daily genistein (G-2535) versus placebo in men with early stage prostate cancer undergoing prostatectomy” (subcontract from University of Wisconsin)

Role: PI: Howard Bailey, MD; Co-investigator: Edward Messing 10/1/10-9/29/12 Total Award: $3,781

Baylor College of Medicine Title: “Clinical application of the COXEN model in a personalized intravesical chemotherapeutic agent selection approach for treatment of intermediate-risk non-invasive bladder cancer: a feasibility study” Role: Seth Lerner, National PI, Edward Messing (PI) Dates of Award: 12/1/11-11/30/13 Total Award: $2,548

NIH/NCI CA37429 (Southwest Oncology Group) Title: Selenium and Vitamin E Cancer Prevention Trial Role: PI: Edward Messing Dates of Award: 10/1/01 – 7/1/13 Total Award: $63,297

National Institutes of Health 1R01CA127548-01 Title: “TR4 orphan receptor, a longevity assurance gene, in prostate carcinogenesis”

Role: YiFen Lee (PI); Co-Investigator – E. Messing Dates of Award: 9/5/08-7/31/13 Total Award: $866,701

National Institutes of Health CA137474 Title: “ER alpha in prostate homeostasis and cancer” Role: ShuYuan Yeh (PI) Co- Investigator E. Messing Dates of Award: 5/1/09-12/31/14 Total Award: $1,003,798 J.P. Wilmot Cancer Center Title: “New Combination BCG Therapy with Targeting AR to Battle Bladder Cancer” Role: Principal Investigator with Chawnshang Chang Dates of Award: 7/1/13-6/30/14 Total Award: $50,000 Cancer and Leukemia Group B Title: Prostate Cancer: The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance (CALGB 70807)” Role: Principal Investigator Dates of Award: 12/1/11- 11/30/15 Total Award: $14,000

https://commons.era.nih.gov/commons/genericStatus.do?actionRole=nonPI&applID=7248113&uhf-token=GPJv%2BLVVicsEFR7gC3d5ygOyFLM%3D


J.P. Wilmot Cancer Center/Roswell Park Cancer Institute Title: “Vitamin D Levels Determine the Efficacy of BCG Immunotherapy for Bladder Cancer” Role: Principal Investigator (with YiFen Lee, Donald Trump, and Khurshid Guru) Dates of Award: 5/14/12-4/30/15 Total Award: $50,000 Abbott Molecular Inc. Title: “Evaluation of the UroVysion test in predicting recurrence and/or progression of disease in patients receiving initial BCG for primary high grade Ta-T1 and CIS urothelial carcinoma of the bladder” Role: Principal Investigator Dates of Award: 1/30/14-1/31/16 Total Award: $21,600 University of Wisconsin/NCI HHSN261201200033I. Title: “Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery “Role: Howard Bailey (PI), Site Investigator E. Messing Dates of Award: 5/1/14-3/31/16 (Ongoing into 2018) Total Award: $22,866 CDC Special Interest Project (SIP-14-014)/ Rochester Prevention Research Center Title: “An Interactive, Clinical Decision Dashboard to Support Treatment Decisions for Men with Low-grade, Local-stage Prostate Cancer” Role: James Dolan (PI) Co- Investigator E. Messing Dates of Award: 9/1/14-8/31/16 Total Award: $821,540 University of Wisconsin/NCI HHSN261201200033I. Title: “Phase IIA Exploratory, Randomized, Placebo-controlled Trial of Pomegranate Fruit Extract/POMx™ in Subjects with Clinically Localized Prostate Cancer Undergoing Active Surveillance” Role: Howard Bailey (PI), Site Investigator E. Messing Dates of Award: 10/1/14-3/31/16 Total Award: $20,000

Cellanyx Diagnostics Title: “Cellanyx Prostate Cancer Diagnostics Feasibility Study” Role: Hani Rashid (PI), Sub-investigator E. Messing Dates of Award: 9/1/15-8/31/16 Total Award: $35,820

Astelllas Scientific Title: “Enzalutamide for Bladder Cancer Prevention” Role: Principal Investigator Dates of Award: 8/1/15 – 7/31/17 Total Award: $137,715


Southwest Oncology Group Title: “A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed At Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer” (S1011) Role: Seth Lerner (PI) Co- Investigator E. Messing Dates of Award: 8/1/11-7/31/17 Total Award: $2,250

National Institutes of Health 1R01CA173986-01A1 Title: “Exosomes: A novel mechanism for bladder cancer tumorigenesis and progression” Role: YiFen Lee (PI), Co- Investigator E. Messing Dates of Award: 1/8/14-12/31/18 Total Award: $1,180,510

Clinical and Translational Science Award 5UL1TR000042-09 Title: “Exosomes from bladder cancer patients can serve as biomarkers of disease” Role: Principal Investigator Dates of Award: 7/1/14- 9/30/18 Total Award: $50,000

SWOG/Hope Foundation

Title: Extracellular vesicle biomarkers for predicting response to BCG therapy Role: Co-PI; Yi Fen Lee, PI Dates of Award: 1/1/17-12/31/18 Total Award: $200,000

Cornell University/NCI

Title: “Targeting the Blood borne Spread of Prostate Cancer” Role: Michael King (PI), co-investigator Edward Messing

Dates of Award: 9/1/15-8/31/20 Imagine Medical

Title: “Assessing Near Infrared Fluorescence Imaging Medical Technology for the Detection of Bladder Cancer (DWELL)”

Role: PI – Edward Messing Dates of Award: 1/1/18-12/31/18 TARIS Biomedical

Title: “A Multicenter Study Evaluating Safety and Efficacy of TAR 200 in Subjects with Muscle-Invasive Urothelial Carcinoma of the Bladder Who are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who are Unfit for Radical Cystectomy”

Role: PI Dates of Award: 1/12/18 -1/31/22

Southwest Oncology Group “A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine Versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer” (S0337) Role: PI Dates: 7/15/07-8/15/12 Altor Biosciences Role: PI Dates of Award: 8/27/18-7/31/20


“QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer Dates of Award: 8/27/18-7/31/20 Southwest Oncology Group Edward Messing (site PI) (Robert Svatek, National PI) “SWOG S1602 (PRIME) - Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer” Dates: 2/7/17 - ongoing

INVITED MODERATOR National and International 1. "Prostate Cancer Research." American Urological Association Annual Meeting, Atlanta, Georgia, May 12,

1985. 2. "Bladder Tumor Research." American Urological Association Annual Meeting, New York, New York,

May 18, 1986. 3. Sessions on "Etiology" and on "Clinical Presentation and Diagnosis of Interstitial

Cystitis." 1st International Interstitial Cystitis Investigators' Workshop, Boston, Massachusetts, September 16, 1986.

4. "Bladder Cancer Detection." American Urological Association Annual Meeting, Anaheim, California, May 1987.

5. "Germ Cell Tumors." North Central Section of American Urological Association Annual Meeting, Detroit,

Michigan, September 1987. 6. "Bladder Cancer Research." American Urological Association Annual Meeting, Dallas, Texas, May 1989. 7. "Immunology of Urologic Tumors." American Urological Association Annual Meeting, Toronto, Ontario,

Canada, June 1991. 8. "Bladder Cancer Hematuria Screening Workshop." Wisconsin Comprehensive Cancer Center, Madison,

Wisconsin, October 1991 (organizer and moderator of meeting). 9. "Bladder Cancer - Diagnosis and Management." American Urological Association Annual Meeting,

Washington, DC, May 1992. 10. "Management of Invasive Bladder Cancer." American Urological Association, San Antonio, Texas,

May 1993. 11. "Superficial Bladder Cancer." American Urological Association, San Francisco, California, May 1994. 12. "Superficial Bladder Cancer." American Urological Association, Las Vegas, Nevada, April 1995. 13. “Translational Research in Urologic Cancers.” Society Urologic Oncologists, Orlando, May 1996.


14. “Superficial Bladder Cancer.” American Urological Association, Orlando, May 1996. 15. “Impotence, Reproductive Biology, Prostate Cancer”. American Urological Association,

Buffalo, New York, September 1996. 16. “Bladder Cancer Research”. American Urological Association, New Orleans, LA. April, 1997. 17. Upstate New York Urological Association 2nd Annual Resident Essay Competition Moderator,

Syracuse, NY. May 1997. 18. “Bladder Cancer: Superficial”. American Urological Association, San Diego, CA. June 1998. 19. “Bladder Cancer – Detection and Screening” - American Urological Association, Dallas, TX. May 1999. 20. "Timing of hormonal therapy of prostate cancer". American Urological Association, Atlanta, GA.

April 2000. 21. Northeast Section of the American Urological Association, 52nd Annual Meeting. Moderator - "BPH, Basic

Science and Transplant". Pittsburgh, PA. September 2000. 22. 25th Annual SIU Congress of Urology - Moderator - "Bladder Cancer Diagnosis" - Singapore.

November 2000. 23. American Urological Association Annual Meeting - Panelist - Bladder Cancer: Common Clinical

Problems. Orlando. May 2002. 24. 54th Annual Northeastern American Urological Association Meeting - Moderator - "Laparoscopy/Trauma

Reconstruction". Quebec, Canada. September 2002. 25. “Oncology and Cellular Biology” – International Bladder Symposium. Arlington, VA. March 2003. 26. Moderator – Northeastern Section American Urological Association Annual Meeting – Nova Scotia,

Sept. 2003 27. “Biomarkers for GU Cancer” – Society of Urologic Oncology. Bethesda, Dec. 2003. 28. Society of Urologic Oncology – Moderator – “Optimal Timing of Early Hormonal Therapy”.

San Francisco, CA. May 2004. 29. American Urological Association Annual Meeting – Moderator – Podium Session “Prostate Cancer:

Advanced”. San Francisco, CA. May 2004. 30. Moderator – North Eastern American Urological Association Annual Meeting - Prostate Cancer Session. “

Savannah – October 2004. 31. Society of Urologic Oncology – Moderator - “Bladder Cancer II: Has the Time Arrived for Screening for

Bladder Cancer” - Bethesda, MD. December 20, 2004. 32. Moderator – 18th Annual Symposium: Disputes and Controversies in Prostate Cancer Diagnosis and

Treatment. Tokyo – January 2005. 33. 2005 Annual American Urological Association Meeting - Moderator: Prostate Cancer – Advanced.

San Antonio – May 2005.


34. Northeast Section American Urological Association - Moderator: Bladder Cancer. Ottawa, CA - September 2006.

35. Northeast Section American Urological Association - Moderator: Prostate Cancer. Rochester, NY – September 2007. 36. Society of Urologic Oncology – Moderator: Prostate Cancer – New Options for hormone refractory

disease. Bethesda, MD – November 2007 37. American Urological Association – Moderator – Prostate Cancer. Orlando, Florida – May 2008. 38. NEAUA Annual Meeting – Moderator - Plenary Session – Androgen Deprivation Therapy -

Montreal, Quebec, Canada – October 2009 39. American Urological Association – Moderator – Bladder Cancer: Basic Research.

San Francisco, CA. May, 2010

40. American Urological Association – Moderator – Bladder Cancer: Basic Research. Washington DC. May, 2011

41. Northeast Section American Urological Association - Moderator: Slotkin Lecture –

New Orleans, October 2011

42. American Urological Association – Moderator – Bladder Cancer: Basic Research. Atlanta, GA. May, 2012

43. Society of Urologic Oncology – Moderator – Immuno-based strategies for therapy for prostate cancer.

San Diego, CA – May 2013

44. Society of Urologic Oncology – Moderator - Coffey Lectureship. San Diego, CA – May 2013

45. American Urological Association – Moderator - Poster Session: Bladder Cancer: Metastatic Disease + Staging. San Diego, CA – May 2013

46. American Urological Association – Moderator – Bladder Cancer: Detection & Screening – Orlando, FL.

May 2014

47. Northeast Section American Urological Association – Moderator – Education Forum: Management of Localized High Risk Prostate Cancer: Upfront Surgery or Radiation – Amelia Island, FL. November 2014

48. American Urological Association – Moderator – Bladder Cancer – New Orleans, LA. May 2015 49. American Urological Association – Moderator – Prostate Cancer Debate – San Diego, CA. May 2016

49. American Urological Association – Moderator – Oncology Surgery – Nerve Sparing – San Francisco, CA.

May 2018 INVITED LECTURESHIPS (Outside of University of Rochester) 1. "Prostatic Cancer." Wisconsin Oncology Group Winter Meeting, Madison, Wisconsin, February 1983. 2. "Management of Non-Seminomatous Testes Tumors." Gundersen Clinic Cancer Conference, La Crosse,

Wisconsin, April 1983.


3. "Growth Factors and Bladder Cancer." Stanford University School of Medicine Division of Urology,

Stanford, California, October 1984. 4. "Management of Early Stage Prostate Cancer." Wisconsin Oncology Group Winter Meeting, Madison,

Wisconsin, December 1985. 5. "Home screening for Hematuria." Stanford University Annual Urology Symposium, Stanford, California,

April 1986. 6. "Inflammation and Infection in Interstitial Cystitis: Diagnosis of Interstitial Cystitis." NIDDK

International Symposium on Interstitial Cystitis, Bethesda, Maryland, October 1987. 7. "Screening for Bladder Cancer." University of Ohio Bladder Cancer Symposium, Toledo, Ohio, June 1988. 8. "Interstitial Cystitis." Chicago Urologic Society/Northwestern University Symposium on Urinary

Infections, Chicago, Illinois, February 1990. 9. "Hematuria Screening for Bladder Cancer." Herman Kretschmar Memorial Lecture, Chicago Urologic

Society, Chicago, Illinois, February 1990. 10. "Screening for Bladder Cancer." NIH Southwest Oncology Group Seminar on Bladder Cancer, Denver,

Colorado, April 1990. 11. "Management of Regional and Locally Metastatic Prostatic Cancer." Philadelphia Urological Society,

Philadelphia, Pennsylvania, November 1990. 12. "Management of Muscle Invading Bladder Cancer." American Urological Association Annual Meeting,

Toronto, Ontario, Canada, June 1991. 13. "Epidermal Growth Factor and Human Bladder Cancer." The Fourth International Symposium of the

Foundation for Promotion of Cancer Research, Tokyo, Japan, March 1991. 14. "Hematuria Screening for Urinary Tract Cancers." Kyoto University, School of Medicine, Department of

Urology, Kyoto, Japan, March 1991. 15. "Bladder Cancer - Clinical and Research Update." NIH mini-symposium, Bethesda, Maryland,

October 1991. 16. "Hematuria Screening and Evaluation." State of Michigan Medical Society Annual Meeting, Detroit,

Michigan, November 1991. 17. "Surgical Management of Prostatic Cancer." Brown County Medical Society Symposium, Green Bay,

Wisconsin, March 1992. 18. "PSA Screening and Current Therapy for Prostate Cancer." 44th Annual Scientific Assembly, Wisconsin

Academy of Family Physicians, Madison, Wisconsin, June 1992. 19. "Which is the Preferable Strategy to Treat Bladder Cancer?" 2nd International Meeting on Debated

Problems in Clinical Oncology, Cagliari, Italy, October 8-9, 1992. 20. "EGF and Bladder Cancer - Growth Factors, Biochemical Background and Clinical Use in Oncology."

Meeting of the Danish Royal Cancer Society, Aarhus, Denmark. October19, 1992.


21. "Treatment in the 21st Century." Medical Advisory Council, Canadian Urological Society, Islamorada, Florida, April 22-25, 1993.

22. "Clinical Implications of EGF and Bladder Cancer." The Japanese College of Surgeons, Omiya, Japan,

June 24, 1993. 23. "Screening for Bladder Cancer." The Japanese Society of Urologic Oncology, Sekaide, Japan,

June 27, 1993. 24. "Screening for Bladder Cancer." Iowa Urological Society, Iowa City, Iowa, September 17-18, 1993. 25. "Management of Small Renal Cancers." Iowa Urological Society, Iowa City, Iowa,

September 17-18, 1993. 26. "Screening for Prostate Cancer." Iowa Urological Society, Iowa City, Iowa, September 17-18, 1993. 27. "Management of Renal Cell Carcinoma." North Central Section, American Urological Association Annual

Meeting, Milwaukee, Wisconsin, October 1, 1993. 28. "EGFr and Bladder Cancer." 2nd Annual Genitourinary Oncology Conference, M. D. Anderson Cancer

Center, Houston, Texas, January 14-15, 1994. 29. "Screening for Bladder Cancer." 2nd Annual Genitourinary Oncology Conference, M. D. Anderson Cancer

Center, Houston, Texas, January 14-15, 1994. 30. “Diagnosis and Management of Localized Prostate Cancer.” Canandaigua Veterans Association,

Canandaigua, October 1995. 31. “Urology and Managed Care.” Corning, New York, October 1995. 32. “Prostate Diseases”, Parkridge Hospital, Rochester, October 1995. 33. “Early Detection of Bladder Cancer”, Cayuga Medical Center, Ithaca, New York, January 1996. 34. “Early Detection and Management of Prostate Cancer, Is It Beneficial”, Robert Packer Hospital, Sayre, PA,

February 1996. 35. “Screening for Prostate Cancer”, Society of Urologic Nurses Conference, Rochester, March 1996. 36. “Clinical Implications of EGF and Bladder Cancer”, International Bladder Symposium, Boston,

March 1996. 37. “Prostate Cancer, PSA and Early Disease”, Urology for Primary Care Physicians, Highland Hospital,

Rochester, May 1996 and Parkridge Hospital, Rochester, New York, June 1996. 38. “Hematuria - Causes and When and How to Evaluate”, Urology for Primary Care Physicians,

Highland Hospital, Rochester, May 1996 and Parkridge Hospital, June 1996. 39. “Screening for Prostate Cancer”, Cayuga Medical Center, June 1996. 40. “Screening for High Risk Bladder Cancer Patients”, September 1996. 41. “Prostate Cancer, PSA and Early Disease Management” and “Hematuria - Causes and When and How to

Evaluate”, Urology for Primary Care Physicians CME Course, Rochester, October 1996.


42. “Hematuria and Screening for Bladder Cancer”, SUNY Syracuse, October 1996. 43. “Bladder Cancer”, Montefiore University, NY City, December 1996. 44. “Latest Treatments for Prostate Cancer”, Rochester Prostate Cancer Men’s Support Group, December 1996. 45. “Prostate Cancer for Primary Care Physicians”, Rochester VA Center, Rochester, January 1997. 46. “Urinary Tract Infections and Interstitial Cystitis”, March 1997. 47. “Diagnosis of Interstitial Cystitis”, Interstitial Cystitis Society, Buffalo, New York, March 1997. 48. “Hematuria and Bladder Cancer”, Cayuga Medical Center, Ithaca, April 1997. 49. “Detection and Management of Early Stage Prostate Cancer”, Retired Physicians Group of the Rochester

Academy of Medicine, Rochester, New York, April 1997. 50. “Early Stage Prostate Cancer”, Canandaigua VA Clinic, Canandaigua, NY, June 1997. 51. “Screening and Treatment of Superficial Bladder Cancer”, New Developments in Cancer Therapy: Focus

on Urologic Cancers. University of Pennsylvania Cancer Center. September 1997. 52. “Hematuria and Screening for Bladder Cancer”, NCI Bladder Cancer Conference,

Sarasota, Florida. January 1998. 53. "Prostate Cancer Treatment and Warning Signs". American Cancer Society, Rochester. August 1998. 54. “Brachytherapy for Prostatic Cancer”, Cayuga Medical Center, Ithaca, NY. October 1998. 55. “Screening for Bladder Cancer”, Philadelphia Urological Society, Philadelphia College of Physicians,

Philadelphia, Pennsylvania. January 1999. 56. “Studies of DFMO in Bladder Cancer”, DFMO Bladder Cancer Investigator’s Meeting, Atlanta, Georgia.

January 1999. 57. "Prostate Cancer Screening and Management", Dansville Regional Lecture Program, Nicholas Noyes

Memorial Hospital, Dansville, NY. March 1999. 58. "Update on Prostate Cancer". Medical/Psychiatrist Services Staff Conference, VA Medical Center,

Canandaigua, NY. June 1999. 59. “Theory and Reported Results of Brachytherapy Computer Program for Intraoperative Optimized

Treatment Planning and Guidance”. Prostate Cancer: “Advances in Diagnosis and Treatment. Rochester Academy of Medicine. June 1999.

60. "Early diagnosis and screening". 3rd International Symposium on Bladder Cancer. Padova, Italy.

September 1999. 61. "Uses of androgen deprivation therapy in prostate cancer". National Urologic Oncology Update.

New York, NY. November 1999. 62. "Timing of hormonal therapy for prostate cancer". "Training of surgery to urology residents". Buffalo

Urological Society Annual Meeting. Buffalo. January 2000.


63. "Hormonal therapy for prostate cancer". Michigan Urological Society, Resident Day Competition. Michigan. May 2000.

64. "Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic

lymphadenectomy in men with node positive prostate cancer". Programme D'Enseignement En Urologie. Quebec. May 2000

65. "Hormonal therapy for prostate cancer - treat now or wait". Western GU Radiation Oncology Forum.

Penticton, British Columbia. June 2000. 66. "Timing of androgen deprivation therapy for prostate cancer". Festschrift Urology Conference - honoring

Thomas Stamey, M.D. Stanford, CA. September 2000. 67. "Management of patient with biochemical failure after definitive treatment for prostate cancer. SIU

Consensus Conference on Immunotherapy for Bladder Cancer. 25th Society of International Urologists Congress of Urology. Singapore. October 2000.

68. "Timing of hormonal therapy in prostate cancer". CME Dinner Program. Philadelphia, PA. October 2000. 69. "Timing of hormonal treatment of prostate cancer"; "Markers of recurrence of bladder cancer"; "Prevention

of bladder cancer"; “Treatment of advanced bladder cancer". Surgical, Pharmacological and Technological Advances in Adult and Pediatric Urology State-of-the-Art. New York University, NY. December 2000.

70. "New concepts in the management of superficial bladder cancer". 2001 Congress on Uro-oncology: A

Canada-Mexico Alliance. Ixtapa, Mexico. January 2001. 71. "Early detection and prevention of bladder cancer". Advances in the Management of Transitional Cell

Carcinoma. Case Western University. Cleveland, OH. March 2001. 72. "Hormonal therapy of prostate cancer". University of Connecticut Symposium. March 2001. 73. "Timing of hormonal therapy for prostate cancer". 1st Annual Charles Huggins Symposium, Current Issues

in the Management of Prostate Cancer. Anaheim, CA. June 2001. 74. "Timing of hormonal therapy for prostate cancer: Does it Matter, If so, When?” Society of Urologic

Surgeons of Ontario. Toronto. September 2001. 75. "Micro-metastatic prostate cancer and the use of hormones". The Prostate Cancer Lecture Series Program.

University of Virginia, VA. October 2001. 76. "Timing of hormonal therapy for prostate cancer". 2001 Fall Visiting Professor, Madison, WI.

November 2001. 77. "Screening, early detection and prevention of bladder cancer". 2001 Fall Visiting Professor, Madison, WI.

November 2001. 78. "Does androgen independent prostate cancer mean independence from the androgen receptor"? 2001 Fall

Visiting Professor, Madison, WI. November 2001. 79. "Management of extensive, local and regional renal cell carcinoma". 2001 Fall Visiting Professor,

Madison, WI. November 2001. 80. "Timing of hormonal therapy in prostate cancer". Current Concepts in Men's Health. Sagamore, Bolton

Landing, NY. August 2002.


81. "Update on new techniques in external beam radiation and brachytherapy". Current Concepts in Men's

Health. Sagamore, Bolton Landing, NY. August 2002. 82. "Hormonal Therapy in Non-Metastatic Prostate Cancer: Its Role and Timing." Current Concepts in Men’s

Health. Sagamore, Bolton Landing, NY. August 2003. 83. "Uroflow in murine urethritis." Research Insights into Interstitial Cystitis symposium. Bethesda, MD.

October 2003. Abstract. 84. “Timing of androgen deprivation.” 3rd Annual Charles Huggins Symposium. Chicago. April 2003. 85. “Bladder cancer prevention.” ”. Urology Update 2003. University of Toronto Department of Surgery,

Division of Urology. Toronto. November 2003. 86. “Timing of Hormonal Therapy for Non-Metastatic Prostate Cancer”. Urology Update 2003. University of

Toronto Department of Surgery, Division of Urology. Toronto. November 2003. 87. “Early vs Delayed Hormonal Therapy”. 3rd Annual Multidisciplinary Genitourinary Oncology Inter-

Continental Conference Center. Cleveland, November 2003. 88. “Markers of detection and prognosis of bladder cancer”. Society of Urologic Oncology Annual Meeting.

Bethesda, December 2003 89. “Adjuvant therapy after radical prostatectomy”; “Timing of hormonal therapy for advanced prostate

cancer”; “Biological markers for bladder cancer” - 2nd Asia-Pacific Society of Uro-Oncology Meeting. Hong Kong, December 2003.

90. “Timing of hormonal therapy for prostate cancer”. Society of Urologic Oncology. San Francisco, CA. May 2004.

91. “Screening and prevention of bladder cancer”. Pelvic Health Educational Initiative AUA Satellite

Symposium. San Francisco, CA. May 2004. 92. “Hematuria Screening”. Franco-US Meeting. San Francisco, CA. May 2004. 93. “Timing of hormonal therapy for prostate cancer”. AUA Think Tank. San Francisco, CA. May 2004 94. “Complications of long-term hormonal therapy – treatment and avoidance” - Current Concepts in Men’s

Health, Albany Medical College, Sagamore – August 2004 95. “Tumor Markers in Bladder Cancer: What are the Indications and Should They be used in Daily Care”.

4th Annual Perspectives in Bladder Cancer Meeting. Seville, Spain – November 2004. 96. “Has the time arrived for screening for bladder cancer?” - Society of Urologic Oncology – Bethesda –

December 2004. 97. “Hormonal therapy for prostate cancer: Timing and Controversies”. 18th International Symposium

Foundation for Promotion of Cancer Research. Tokyo, Japan – January 2005 98. “Optimizing androgen deprivation therapy” - 2005 Multidisciplinary Prostate Cancer Symposium –

Orlando – February 2005.


99. “Timing and indications for androgen deprivation therapy” – American Society of Clinical Oncology – Orlando - May 2005

100. “Markers of Detection of Bladder Cancer” - Bladder Cancer Think Tank - Aspen, Colorado –

August 2006 101. “Results of Bladder Cancer Screening” - Western Ontario Urology Symposium – Ontario, Canada –

September 2007 102. “Androgen deprivation therapy: timing, indications & controversies” - Western Ontario Urology

Symposium – Ontario, Canada – September 2007 103. “Screening for urologic cancers”. SIU Annual meeting – Paris, France – Sept. 2007 104. “What to do when the nodes are positive? Intra-op and post-op decision making.” 15th Innovations in

Urologic Practice. Santa Fe, New Mexico – October 2007 105. “Management of small renal masses: When to watch and wait, when to ablate, and when to operate.” 15th

Innovations in Urologic Practice. Santa Fe, New Mexico – October 2007 106. “Designing the ideal prospective marker trial: what would it look like and what questions could be

addressed”. BCAN’s Bladder Cancer Think Tank III meeting – Mt. Tremblant, Quebec, August 2008. 107. “Androgen deprivation for advanced prostate cancer – Why does it fail and what comes next?” – 7th Annual

Current Concepts in Men’s Health – Sagamore, Albany – August 2008 108. “Treatment of Men with Advanced Prostate Cancer who Fail ADT” - 8th Annual Current Concepts in Mens

Health – Sagamore, Albany – August 2009 109. “Androgen Deprivation Therapy for Prostate Cancer” - NEAUA Annual Meeting – Montreal, Quebec,

Canada – October 2009 110. “Screening for Prostate Cancer” - Nursing Program - NEAUA Annual Meeting – Montreal, Quebec,

Canada – October 2009 111. “Initial Management of Non-muscle Invasive Bladder Cancer: Intravesical BCG”. Current Concepts in

Mens Health 2010. Sagamore, Albany – August 2010.

112. “Post RP, pT3-4 N0 or Margin + CaP: Adjuvant RT vs Observe + Salvage RT: PRO Adjuvant RT”. Current Concepts in Men’s Health, 2011. Sagamore – August 2011.

113. “Bladder Cancer Screening – Discussion” - Bladder Cancer Think Tank – Stowe, Vermont - August 2012

114. “Prostate Cancer in the Elderly” - Current Concepts in Men’s Health – Sagamore, Albany – August 2012

115. “Management of Non-Muscle Invading Bladder Cancer: Initial Treatment and Treatment Failures”.

International Symposium on Uro-Oncology. Buffalo, NY. August 2012

116. “Major Determinant of Survival in Bladder Cancer: The Patient and the Urologist”. Current Concepts in Men’s Health. Lake Placid, NY. August 2014.

117. “Management Castrate Resistant Prostate Cancer (CRPC)”. Current Concepts in Men’s Health.

Saratoga Springs, NY. August 2015. 118. “What are urologists to do in the treatment of NMI BC in the face of the BCG shortage?” South Central


Section AUA. Scottsdale, AZ. October 2015. 119. “Urologists embracing Level 1 evidence: An oxymoron”? Slotkin Lecture. Northeast Section AUA Annual Meeting, Buffalo, NY, September 2016 120. “Help! Too Sick for Cystectomy and BCG Failed”. Current Conceptions in Men’s Health. Saratoga Springs, NY. August 2016. 121. “Anything New Since Huggins? Treatment for Metastatic Androgen Sensitive Disease”. Current Conceptions in Men’s Health. Saratoga Springs, NY. August 2017. 122. “Low and Intermediate Risk – Intravesical Chemotherapy” - Biology and Therapy of Non-Muscle Invasive Bladder Cancer: A Johns Hopkins Greenberg Bladder Cancer Institute/American Urological Association Translational Research Collaboration. Baltimore, Maryland. March, 2018. 123. “State of the Art: Intravesical Chemotherapy TURBT”. 17th Annual Current Concepts in Men’s Health. Saratoga Springs, NY. August 2018. 124. “Bladder Cancer: State of the Science”. Advancing Bladder Cancer Research. A US-Israel Forum for Collaboration. Linthicum, MD. February 2019. INVITED WORKSHOPS 1. "Bladder Cancer Screening." NIH sponsored, Bethesda, Maryland, August 1987. 2. "Interstitial Cystitis." NIH sponsored, Bethesda, Maryland, March 1987. 3. "International Symposium on Interstitial Cystitis." NIH sponsored, Bethesda, Maryland, October 1987. 4. "Cancer Control in Community Hospitals." NIH sponsored, Bethesda, Maryland, November 1987. 5. "Research in Urology - Select Workshop." American Urologic Association sponsored, Houston, Texas,

July 1988. 6. "Transformation of Normal Bladder Epithelial Cells." 1st International Symposium on Bladder Cancer,

Kerkrade, The Netherlands, September 1988. 7. "The Biology of Bladder Cancer: Potential Clinical Implications." NCI-Organ Systems Coordinating

Center, Bethesda, Maryland, March 1989. 8. "Early Detection of Bladder Cancer by Hematuria Home screening Using Urinary Dipsticks." International

Conference on Bladder Cancer Screening in High Risk Groups, Cincinnati, Ohio, September 1989. 9. "Selected Prospects for Bladder Cancer Detection and Prevention." Southwest Oncology Group

Symposium on Bladder Cancer Control, Denver, Colorado, April 1990. 10. "Fundamental and Clinical Research in Urogenital Cancer." The Fourth International Symposium of the

Foundation for Promotion of Cancer Research, Tokyo, Japan, March 1991. 11. "Workshop on Future Research in Bladder Cancer." Organizing Committee, NIH-NIDDK sponsored,

Bethesda, Maryland, October 1991.


12. "Workshop on Prostate and Bladder Biomarkers." National Research Council Subcommittee on Biologic Markers in Urinary Toxicology, Oklahoma City, Oklahoma, January 1992.

13. "Workshop on Hormonal Therapy for Early Stage Prostate Cancer." National Cancer Institute, Bethesda,

Maryland, March 1992. 14. "Chemoprevention of Premalignant and Early Malignant Tumors of the Bladder." National Cancer

Institute, Taos, New Mexico, August 1992. 15. Bladder Marker Network Meeting, Rochester, August 1995. 16. Interstitial Cystitis Data Base Conference, Bethesda, January 1996. 17. “Ultrasonically Guided Radioactive Seed Implantation for the Treatment of Prostate Cancer”, Seattle,

August 1996. 18. Association of American Cancer Institute’s Annual Meeting, Seattle, October 1996. 19. Harvard School of Public Health, Program for Chiefs for Clinical Services. Boston, January 1997. 20. Cancer Center Directors Workshop, Maryland, March 1997. 21. American Urological Association New Urology Chairs Management Workshop. Texas, May 1997. 22. WHO International Workshop. Washington, D.C., October 1997. 23. "Immediate Hormonal Therapy vs. Observation for Node Positive Prostate Cancer following Radical

Prostatectomy and Pelvic Lymphadenectomy: A Randomized Phase III Eastern Cooperative Oncology Group/Intergroup Trial". Presented at Eastern Cooperative Oncology Group. Baltimore, MD. June 1999.

24. "Early Diagnosis and Screening". 3rd International Symposium on Bladder Cancer. Padova, Italy.

September 1999. 25. "In vitro Diagnostics - current status, current research". Bladder Cancer State of the Science Workshop.

Bethesda, MD. September 2000. 26. NIDDK Bladder Progress Review Group Meeting. Bethesda. February 2001. 27. Targeted Cryoablation of the Prostate Physician Training Workshop. NYU. March 2001. 28. “Can the newer diagnostic markers replace cytology and/or cystoscopy?" - International Consultation on

the Diagnosis of Non-invasive urothelial neoplasms. Ancona, Italy. May 2001. 29. Cryosurgery: Ablation of the Prostate - Clinical Applications Workshop. Pittsburgh. October 2001. 30. Astra Zeneca International EPC Workshop - EPC Trial Program and Efficacy and Tolerability Results.

Boca Raton. January 2002. 31. Prostate Cancer Education Project. Miami. February 2002. 32. DFMO Bladder FDA Meeting. Bethesda. March 2002. 33. Astra Zeneca International Speakers Update Workshop - EPC Trial Program and Efficacy and Tolerability

Results. Washington, DC. June 2002.


34. Prostate Cancer Trialist's Collaborative Group (PCTCG) Update Meeting. Amsterdam. July 2002. 35. Prostate Cancer Trialist's Collaborative Group (PCTCG) Meeting. Oxford, England. September 2002. 36. 2nd Annual Superficial Bladder Cancer Advisory Board Meeting. Rome, Italy. September 2002. 37. Sankyo Pharma Development – Consultant - New York City – February 2003. 38. International Bladder Symposium. Virginia, March 2003 39. Hormonal Therapy for Prostate Cancer Advisory Board. Orlando – February 2005 40. Imaging Science Development for Cancer Prevention and Preemption Workshop. Gaithersburg, MD

July 2006. 41. International Bladder Cancer Workshop. Houston, TX – January 2007

42. Novel Neoadjuvant Therapy for Bladder Cancer Workshop. NCI – Gaithersburg, MD – September 2011 VISITING PROFESSORSHIPS 1. "Treatment of Advanced Prostatic Cancer." University of Washington School of Medicine, Department of

Urology, Seattle, Washington, February 1984. 2. "Epidermal Growth Factor and Human Bladder Cancer" and "Screening for Urinary Cancer." University of

Iowa School of Medicine, Department of Urology, Iowa City, Iowa, March 1987. 3. "Management of Cancer of the Penis." University of Minnesota School of Medicine, Department of

Urology, Minneapolis, Minnesota, November 1987. 4. "Hematuria Screening for Urologic Malignancies." University of Colorado School of Medicine,

Department of Urology, Boulder, Colorado, May 1988. 5. "Clinical Implications of EGF and Bladder Cancer", "Diagnosis and Management of Interstitial Cystitis",

and "Screening for Bladder Cancer." Temple University School of Medicine, Department of Surgery, Philadelphia, Pennsylvania, November 1990.

6. "Early Detection of Prostatic and Bladder Cancer." Howard Young Medical Center, Woodruff, Wisconsin,

February 1992. 7. "Growth Factors and Bladder Cancer." Kyoto University, Kyoto, Japan, June 28, 1993. 8. “Hematuria and Screening for Bladder Cancer”, Health Sciences Center at SUNY, Syracuse. October 1996. 9. “Screening for Bladder Cancer”, Montefiore Hospital - Albert Einstein Medical Center, New York City,

December 1996. 10. “Screening for Bladder Cancer”, 19th Annual Congress of the Urological Association of the Republic of

China. Taiwan, August 1997.


11. "Hormonal Therapy of Prostate Cancer". University of Beijing, China. August 1998. 12. "Hormonal Therapy for Prostate Cancer". Michigan Urological Society, Resident Day Competition.

Michigan. May 2000. 13. "Immediate hormonal therapy combined with observation after radical prostatectomy and pelvic

lymphadenectomy in men with node positive prostate cancer". Programme D'Enseignement En Urologie. Quebec and Montreal. May 2000.

14. "Timing of hormonal therapy in prostate cancer" - SUNY Syracuse Prostate Cancer Lecture Series

Program. Syracuse. March 2001. 15. "Detection and prevention of bladder cancer" - Astra Zeneca Speaker's Bureau Lecture Series, Minnesota.

October 2002. 16. “Timing of hormonal therapy in prostate cancer.” Visiting Professor, Minn Dept. of Urology, Minnesota –

October 2002.

17. “Rising PSA after prostatectomy.” Long Island Jewish Medical Center, New York – June 2003. 18. “Timing of hormonal therapy for prostate cancer”. Visiting Professor, University of Wisconsin, Madison –

March 2004. 19. “What’s new in prostate cancer”? Visiting Professor, University of Wisconsin, Madison – March 2004. 20. “Hormonal therapy for non-metastatic prostate cancer: Timing and controversies” – Singapore University

– Grand Rounds Speaker – January 2005. 21. “Screening for Bladder Cancer” - Roswell Cancer Institute, Buffalo, NY – August 2007 22. “Androgens, androgen deprivation therapy and prostate cancer: Why it works (sometimes) and why it

usually fails.” Section of Urologic Surgery – University of Nebraska Medical Center. April 2008.

23. “Bladder Cancer 2011: Clinical Challenges and Opportunities” – The Urology Center of Colorado – November 2011

24. “PSA Screening – Is the USPSTF Correct?” - University of Manitoba, Winnipeg, MB - April 2012

25. “Reducing Mortality from Bladder Cancer” - University of Manitoba, Winnipeg, MB - April 2012

26. “Prostate Cancer in the Elderly” - Royal College of Physicians and Surgeons of Canada - University of Toronto, CA - November 2012

27. “Reducing Mortality from Bladder Cancer” – “Gender and Bladder Cancer: Sex Matter” – “Prostate Cancer in the Elderly” – Henry Ford West Bloomfield Hospital /Vattikuti Urology Institute – June 2014

28. “Urologists Embracing Level I Evidence: An Oxymoron?” – MD Anderson Cancer Center – Houston, TX

– November 2015

29. “Management of patients with HG NMI bladder cancer who fail BCG and are too sick for cystectomy” – BCAN Think Tank. North Carolina, August 2017

30. “Treatment of metastatic androgen sensitive prostate cancer: Is there anything new since Huggins?” – 17th Annual Current Concepts in Men’s Health, Saratoga Springs, NY – August 2017


31. “Low and intermediate risk bladder cancer: Intravesical chemotherapy” – Biology and Therapy of Non-Muscle Invasive BC Conference – Johns Hopkins Medical Center – March 2018

32. “Intravesical chemotherapy post TURBT” – BCAN Think Tank. Denver, CO – August 2018

33. “Androgen and estrogen receptor signaling affecting treatments for bladder cancer: chemotherapy, radiation and BCG” – Albert Institute for Bladder Cancer Research – September 2018

34. “Bladder Cancer: State of the Science”. US-Israel Forum for Collaboration. Linthicum, MD. February 2019

35. “Post-operative Intravesical Chemotherapy” – Masterclass on Bladder Cancer –Roswell Park Cancer Institute – Buffalo, NY – May 2019

36. “Intravesical chemotherapy for low and intermediate risk bladder cancer” – 18th Annual Current Concepts in Men’s Health – Saratoga Springs – August 2019

37. “Management of Low and (low) Intermediate Risk Bladder Cancer” – The Robert Larner MD College of Medicine – Burlington, VT – October 2019

INVITED SITE VISITS, REVIEW COMMITTEES, ETC. 1. Hearing - Flutamide for Therapy of Prostatic Cancer. Food and Drug Association, Urologic Consultant,

Bethesda, Maryland, February 1988. 2. Ad hoc Review Committee - Flow Cytometry Network for Bladder Cancer. National Institutes of Health,

National Cancer Institute, Boston, Massachusetts, July 1988. 3. Site Visit Review Committee - Markers in Bladder Cancer - Program Project. National Institutes of

Health, National Cancer Institute, Memorial Sloan Kettering Cancer Center, New York, New York, December 1988.

4. Messing EM: Special Reviewer of Grant - "EGF/Receptor in Oral Cavity: Effect of Cigarette Smoking."

National Institutes of Health - Oral Biology and Medicine Study section, September-October 1991. 5. Scientific Review Committee - Research and Development Projects in Chemoprevention. National

Institutes of Health, National Cancer Institute, Bethesda, Maryland, July 1993. 6. Review Committee - FDA Office of Orphan Product Development, December 1996. 7. National Cancer Institute Site Review - UCLA, June 1997. 8. National Cancer Institute Kidney/Bladder Progress Review Group - Director: Bladder Cancer Research;

Co-Director: Bladder Cancer Prevention - Virginia, July 2001. 9. USAMRMC 2001 Prostate Cancer Research Program Review Meeting - Prostate Cancer Research

Program. Vienna, VA. August 2001. 10. Department of Defense Grant Review Committee – Reviewer - June 2006

11. AUA Urology Care Foundation – Grant Reviewer – November 2019


12. Yorkshire Granting Agency – Yorkshire, England – Grant reviewer – December 2019 PRESENTATIONS (Peer-Reviewed) National and International 1. Messing EM: "Serum-Free Medium for Human Bladder Cancer." American Association of Cancer

Researchers, St. Louis, Missouri, May 1982. 2. Messing EM: "Transitional Cell Carcinoma Antigens Detected by Monoclonal Antibodies." American

Urological Association Annual Meeting, Kansas City, Missouri, May 1982. 3. Messing EM: "Growth Factors and Transitional Cell Carcinoma: Their Interaction Evaluated With the Aid

of Serum-Free Medium." American Urologic Association Annual Meeting, Kansas City, Missouri, May 1982.

4. Messing EM: "Growth Stimulating Activity Produced by Human Bladder Cancer Cells." Surgical Forum

of the American College of Surgeons Annual Congress, Atlanta, Georgia, October 1983. 5. Messing EM. "Chemosurgery for Penile Cancer." American Urological Association Annual Meeting, New

Orleans, Louisiana, April 1984. 6. Messing EM. "Transforming Growth Factors from Human Bladder Cancer." Surgical Forum of the American College of Surgeons Annual Congress, San Francisco, California, October 1984. 7. Messing EM. "Adrenal Cortical Carcinoma." North Central Section of American Urological Association

Annual Meeting, Des Moines, Iowa, November 1984. 8. Messing EM. "Detrusor Reinforcement with Rectus Femoris Pedicle Flaps." American Urological

Association Annual Meeting, Atlanta, Georgia, May 1985. 9. Messing EM. "Transforming Growth Factors Produced by Bladder Carcinoma." American Urological

Association Annual Meeting, Atlanta, Georgia, May 1985. 10. Messing EM. "Ornithine Decarboxylase Activity of Human Bladder Cancer." Surgical Forum of the

American College of Surgeons, Annual Congress, Chicago, Illinois, October 1985.

11. Messing EM. "Nonseminomatomous Germ Cell Tumors of the Testicle." American Urological Association Annual Meeting, New York, New York, May 1986.

12. Messing EM. "Polyamine Synthesis Inhibition: Effect on Human Bladder Cancer." American Urological

Association Annual Meeting, New York, New York, May 1986. 13. Messing EM. "Normal and Malignant Urothelial Cells: Response to Epidermal Growth Factor and

Ornithine Decarboxylase Blockade." Surgical Forum of the American College of Surgeons Annual Congress, New Orleans, Louisiana, October 1986.

14. Messing EM. "EGF and Human Bladder Cancer: In Situ Studies." American Urological Association

Annual Meeting, Anaheim, California, May 1987. 15. Messing EM. "Home screening for Hematuria to Detect Urinary Tract Cancers." American Urological

Association Annual Meeting, Anaheim, California, May 1987.


16. Messing EM. "Polyamine Metabolism and Bladder Cancer." American Urological Association Annual

Meeting, Boston, Massachusetts, May 1988. 17. Messing EM. "Epidermal Growth Factor and Bladder Cancer: Clinical Implications." American

Urological Association, Annual Meeting, Dallas, Texas, May 1989. 18. Messing EM. "Binding and Response to Epidermal Growth Factors by In Vitro Transformants of Normal

Human Urothelial Cells." American Urological Association, Annual Meeting, New Orleans, Louisiana, May 1990.

19. Messing EM. "Detection of Urologic Cancers by Hematuria Screening." American Urological Association

Annual Meeting, Toronto, Ontario, Canada, June 1991. 20. Messing EM. "Hematuria Home screening: Repeat Testing 9 Months after Negative Tests." American

Urological Association Annual Meeting, Washington, DC, May 1992. 21. Messing EM. "Urinary Excretion of Epidermal Growth Factor in Patients with Bladder Cancer." American

Urological Association Annual Meeting, Washington, DC, May 1992. 22. Messing EM. "Reduced Bladder Cancer Mortality by Hematuria Home Screening." North Central Section,

American Urological Association Annual Meeting, Milwaukee, Wisconsin, October 1, 1993. 23. Messing EM. "Early Detection of Bladder Cancer (BC) by Hematuria Screening Reduces BC Mortality."

American Urological Association Annual Meeting, San Francisco, California, May 1994. 24. Messing EM. "Cost-Effectiveness of Screening for Bladder Cancer using Chemical Reagent Strips to

Detect Microscopic Hematuria." American Urological Association Annual Meeting, Las Vegas, Nevada, April 1995.

25. Messing EM. "Ornithine Decarboxylase Activity in Normal and Malignant Urothelium - Implications for

Prevention and Treatment of Bladder Cancer." American Urological Association Annual Meeting, Las Vegas, Nevada, April 1995.

26. Messing EM, Kryger JV. "Cryosurgical Ablation of the Prostate in a Canine Model." American Urological

Association, North Central Section Meeting, Minneapolis, Minnesota, September 1995. 27. Messing EM. "Deletions on Chromosome 14Q as Determined by FISH Are Associated With Poor

Prognosis in Renal Cell Carcinoma (RCC)." American Urological Association, Northeastern Section Meeting, Cairo, Egypt, October 1995.

28. Messing EM. "Ornithine Decarboxylase (ODC) Blockade--A Potential Approach to Bladder Cancer (BC)

Prevention." American Urological Association, Northeastern Section Meeting, Cairo, Egypt, October 1995.

29. Messing EM. “Correlating Cystoscopic Findings with Symptoms and Physical Exam Findings for Women

with Interstitial Cystitis.” American Urological Association, Orlando, May 1996. 30. Messing EM. "Deletions on Chromosome 14Q as Determined by FISH Are Associated With Poor

Prognosis in Renal Cell Carcinoma (RCC)." American Urological Association, Orlando, May 1996. 31. Messing EM. "Intraoperative real time planning for prostate brachytherapy". American Urological

Association, NE Section Annual meeting. Canada, October 1998.


32. Messing EM. “Immediate Hormonal Therapy vs Observation for Node Positive Prostate Cancer following Radical Prostatectomy and Pelvic Lymphadenectomy: A Randomized Phase III Eastern Cooperative Oncology Group/Intergroup Trial”. American Urological Association, Dallas, May 1999.

33. Messing EM. "Timing of hormonal therapy for prostate cancer". American Urological Association Annual Meeting. Atlanta. April 2000.

34. Messing EM. "CAG repeats within the androgen receptor gene in black and white men with local stage

prostate cancer". American Urological Association Annual Meeting. Anaheim, June 2001. 35. Messing EM. "Does grade of initial bladder cancer predict that of recurrences?" American Urological

Association, Northeastern Section. Boca Raton, December 2001. 36. Messing, EM. "Outcome of surgical treatment for renal cell carcinoma (RCC) with vena caval

involvement: Results of EST2886". American Urological Association, Northeastern Section. Boca Raton, December 2001.

37. Messing, EM. "Lessons learned from prostate cancer trials". Society of Urologic Oncology. Orlando.

May 2002. 38. Messing EM. "Monitoring superficial bladder cancer". American Urological Association Annual Meeting.

Orlando. May 2002. 39. Messing, EM. "Intraoperative treatment planning and guidance for prostate brachytherapy: Results of a

prospective randomized study". 54th Annual Northeastern AUA Meeting. Quebec, Canada. September 2002.

40. Messing, EM. “Late hormonal therapy for biochemical failure: sometimes”. NCI Society of Urologic

Oncology. Bethesda. December 2002. 41. Messing, EM. “Late hormonal therapy for biochemical failure: sometimes”. NCI Society of Urologic

Oncology. Bethesda. December 2002. 42. Messing, EM. “Immediate hormonal therapy compared with observation after radical prostatectomy and

pelvic lymphadenectomy in men with node positive prostate cancer: Results at 10 years of EST3886.” American Urological Association Annual Meeting, Chicago – April 2003

43. Joseph, JV. Madeb, R. Wu, G. Vicente, I. Huang, J. Messing, E. Erturk, E. “Early Functional Results

Following Laparoscopic Radical Prostatectomy”. 55th Annual Northeastern AUA Meeting. Nova Scotia, Canada. September 2003.

44. Messing, EM. “Markers of detection and prognosis of bladder cancer”. Society Urology Oncology,

Bethesda. December 2003. 45. Messing, EM. “Monitoring superficial bladder cancer with the ImmunoCyt fluorescent cytology test”.

Podium presentation. American Urological Association Annual Meeting. San Francisco, CA. May 2004. 46. Messing, EM. “Immediate vs delayed hormonal therapy in patients with nodal positive prostate cancer who

had undergone radical prostatectomy and pelvic lymphadenectomy: Results of Central Pathology Review. Abstract accepted at Podium Session. American Urological Association Annual Meeting. San Francisco, CA. May 2004.

47. Messing EM. “Bladder Cancer II: Has the time arrived for screening for bladder cancer”. Society Urologic

Oncology/National Cancer Institute Annual Meeting. Bethesda – December 2004.


48. Messing, EM. “A randomized prospective phase III trial of Difluormethylornithine (DFMO) vs placebo in

preventing recurrence of completely resected low risk superficial bladder cancer. Abstract accepted at Podium Session. American Urological Association Annual Meeting. San Antonio, TX. May 2005.

49. Katz G, Messing EM. “Diagnosis of bladder cancer using a point of care proteomic assay: A Multi-center study. Abstract accepted at American Urological Association Annual Meeting. San Antonio, TX. May 2005.

50. Messing, EM. “Timing and indications for androgen deprivation therapy”. American Society of Clinical

Oncology. Orlando – May 2005. 51. Podder TK, Messing EM, Rubens DJ, et al. Brachytherapy needle insertion: An in vivo data analysis.

Paper accepted for presentation at the 14th International Conference of Medical Physics (ICMP). Nuremberg, Germany. September 2005.

52. Take Home Message Presenter: Advanced Prostate Cancer – 2005 Annual American Urological

Association Plenary Session – San Antonio – May 2005 53. “A randomized prospective phase III trial of Difluormethylornithine (DFMO) vs placebo in preventing

recurrence of completely resected low risk superficial bladder cancer” - 2005 Annual American Urological Association Meeting – San Antonio – May 2005

54. “Long-term outcome of hematuria home screening for bladder cancer” - Presented at the 2005 Annual

American Urological Association Meeting – San Antonio – May 2005 55. “Long-term outcome of patients with a negative work-up for asymptomatic micro-hematuria” – Podium

session - 2006 Annual American Urological Association Meeting – San Antonio – May 2006 56. “Non-bladder cancer causes of death among patients with newly diagnosed bladder cancer”. Podium

session – Annual American Urological Association Meeting – Anaheim – May 2007 57. “Impact of robotic prostatectomy on residency training”. Presented at 3rd World Congress Urologic

Oncology Conference – Paris, France – September 2007 58. “Screening for Urologic Malignancies”. Society of International Urologists – Paris, France –

September 2007 59. “Expression of frizzled-8 in the bladder Urothelium of interstitial cystitis patients. Podium session –

Northeast Section Annual American Urological Association Meeting – Rochester – September 2007 60. “The Von Hippel Lindau tumor suppressor is a regulator of p53 in renal carcinoma cell genotoxic

response”. Podium session – Northeast Section Annual American Urological Association Meeting – Rochester – September 2007

61. “Intraoperative imaging of renal cortical tumors using near infrared fluorescence of intravenous

indocyanine green”. Podium session – Northeast Section Annual American Urological Association Meeting – Rochester – September 2007

62. “Gender and racial differences in bladder cancer mortality: How much of a role do tumor factors at presentation play?” American Association of Genitourinary Surgeons Annual Meeting – Naples, Florida. April 2008


63. “Gender and Racial Differences in bladder cancer mortality: How much of a role do tumor factors at presentation play?” Podium session - Annual American Urological Association Meeting, Orlando, Florida – May 2008.

64. “Presentation of Bladder Cancer in the United States: Differences Based on Gender, Race, and Age”.

Podium session - Annual American Urological Association Meeting, Orlando, Florida – May 2008. 65. “Treatment of Men who Failed ADT”. Society of Basic Urologic Research – Fall Symposium – Phoenix,

AZ – November 2008 66. “Phase III Study of Genistein in Patients with Bladder Cancer”. American Association for Cancer

Research – National Harbor – Maryland – November 2008 67. “Do outcomes from squamous cell and urothelial carcinoma of the bladder differ when adjusting for

stage?” - Podium session - Annual American Urological Association Meeting – Chicago, April 2009 68. “Soy isoflavone G-2535 and Bladder Cancer: Molecular effects in tumor tissue and urine”. American

Association of Genitourinary Surgeons Annual Meeting – La Jolla, CA – April 2009 69. “Soy isoflavone G-2535 and Bladder Cancer: Molecular effects in tumor tissue and urine”. Poster Session – NEAUA Annual Meeting – Montreal, Quebec, Canada – October 2009 70. “Florescence Cystoscopy with Hexaminolevulinate (HAL) improves detection rate of Ta and T1 bladder

cancer and reduces recurrence following TURBT at 9 months”. Poster session - NEAUA Annual Meeting – Montreal, Quebec, Canada – October 2009

71. “Do mixed histologic features affect survival benefit from Neoadjuvant platinum-based combination

chemotherapy in patients with locally advanced bladder cancer?” Oral presenter and poster session: 2010 Genitourinary Cancers Symposium – ASCO/SBUR/SUO. March, 2010.

72. “Do mixed histologic features affect survival benefit from Neoadjuvant platinum-based combination

chemotherapy in patients with locally advanced bladder cancer treated with radical cystectomy”? American Association of Genitourinary Surgeons. Santa Ana Pueblo, New Mexico – May, 2010. 73. “Do mixed histologic features affect survival benefit from Neoadjuvant platinum-based combination

chemotherapy in patients with locally advanced bladder cancer” – Poster session - American Urological Association Annual Meeting – San Francisco, CA. May 2010

74. “Analysis of tocopherol-associated protein (tap) expression in prostate cancer and its correlation with

clinic-pathologic features”. Poster session - North Eastern American Urological Association Annual Meeting – New Orleans, October 2011.

75. “Prostate cancer in the Elderly: Frequency of Advanced Disease at Presentation and Disease-Specific

Mortality” – Poster Session - Society of Urologic Oncology Annual Meeting – Bethesda, December 2011

76. “Prostate cancer in the Elderly: Frequency of Advanced Disease at Presentation and Disease-Specific Mortality” – Poster Session - American Urological Association – Annual meeting - Atlanta – May 2012

77. “Expression of androgen and estrogen receptors and its prognostic significance in urothelial neoplasm of

the urinary bladder”. Podium session - American Urological Association – Annual meeting - Atlanta – May 2012


78. “Capture and analysis of prostate cancer stem cells using a microcirculatory channel” – Moderated poster - American Urological Association – Annual meeting - Atlanta – May 2012

79. “Vitamin D and BCG immunotherapy” - Moderated Poster - American Urological Association – Annual

meeting - Atlanta – May 2012

80. “Incidence of bladder cancer as a secondary malignancy in patients treated with radiation for cervical cancer” - Moderated poster - American Urological Association – Annual meeting - Atlanta – May 2012

81. “Prostate-specific antigen testing in older men in the United States: Data from the Behavioral Risk Factor

Surveillance System” - Moderated poster - American Urological Association – Annual meeting - Atlanta – May 2012

82. “Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: A meta-

analysis of eight cohort studies” - Moderated poster - Northeastern American Urological Association – Annual meeting - Niagara Falls, Ontario, CA – September 2012

83. “Renal functioning after nephron-sparing surgery vs radical nephrectomy: results from the EORTC trial

30904” – Moderated poster session, American Urological Association, San Diego, CA – May 2013

84. “Molecular markers for risk, diagnosis and prognosis in prostate cancer” - Panel Discussion - American Urological Association, San Diego, CA – May 2013

85. “Management of localized high-risk prostate: upfront surgery or radiation” – Educational forum -

Northeastern Section, American Urological Association, Amelia Island, FL – November 2014

86. “The long non-coding RNA HOTAIR affects exosome-mediated bladder cancer Progression” - Poster session abstract – American Association for Cancer Research, Philadelphia, PA – April 2015

87. “ERα prevents bladder cancer via INPP4B inhibition of AKT”- Presentation - American Association of Genitourinary Surgeons, San Francisco, CA – April 2015 88. “Glycolytic and Inflammatory Pathway Genes Are Overexpressed in Bladder Cancer Tumors”. American Urological Association meeting. San Diego, CA. May 2016. Abstract. 89. “Full procedural simulation for transurethral resection of bladder tumors (TURBT) using 3-D printing technology”. American Urological Association meeting. San Diego, CA. May 2016. Abstract. 90. “A phase III blinded study of immediate post-TURBT instillation of gemcitabine vs saline in patients with newly diagnosed or occasionally recurring low grade non-muscle invading bladder cancer: SWOG S0337 (NCT 0045601)”. American Urological Association Annual Meeting, Boston, MA – May 2017.

91. “A phase III blinded study of immediate post-TURBT instillation of gemcitabine vs saline in patients with

newly diagnosed or occasionally recurring low grade non-muscle invading bladder cancer: SWOG S0337”. American Association of Genito-urinary Surgeons (AAGUS) Annual Meeting. Key Biscayne, FL. April 2017.

92. “Post-TUR Mitomycin C Debate: Should it Be Standard of Care”? Society of Urologic Oncology Annual Meeting. Washington DC. November, 2017. 93. “Immediate Post TURB Intravesical Gemcitabine: A cost comparison based on SWOG S0337”. American Association of Genito-urinary Surgeons (AAGUS) Annual Meeting. Scottsdale, AZ. April 2018.


94. “Immediate Post TURB Intravesical Gemcitabine: A cost comparison based on SWOG S0337”. Abstract presentation. American Urological Association Annual Meeting. San Francisco, CA. May 2018. 95. “NMIBC and Intravesical Treatments” Virtual Presentations. Urology Teaching Collaborative. April

2020 PhD THESES – Committee Member 2002 Cheng-Lung Hsu - Characterizations of ligand-dependent androgen receptor associated peptides and proteins

Saleh Tuwaijri - Interruption of NF-kB signaling by androgen receptor

facilitates TPA-induced apoptosis via JNK in an androgen sensitive prostate cancer cell line

Leslie Kate O. Wright - Function of DBCCR1, deleted in bladder cancer chromosome region 1

Zaibo Li - Identification of a ubiquitin specific processing protease subfamily as the downstream targets of the von Hippel-Lindau tumor suppressor

2003

Yu Zhang – The evaluation of Vitamin E succinate target gene in vitro and in vivo in prostate cancer

Xi Na - Characterization of vonHippel Lindau tumor suppressor functions in renal cell carcinoma.

2004 Dakun Wang - Two novel MET-interacting proteins, RanBP9 and RanBP10,

share high sequence similarity, but differ in their effects on Ras-Erk signaling

Yanqing Zhang - Identification and characterization of ARA67/PAT1 as a negative regulator of androgen receptor-mediated signaling

Cheng-Lung Hsu - Identification and characterization of liganded androgen receptor COOH- terminus associated peptides and peptide motifs

Saleh Altuwaijri – Androgen receptor modulates the immune response and suppresses metastasis of prostate cancer

Jing Ni – The Effect of Vitamin E succinate on prostate cancer angiogenesis in vitro and in vivo 2006 Aimee Johnson - Gender and Bladder Cancer Xiangrong He - Characterization of novel functions of the von Hippel-Lindau tumor suppressor protein in renal cell carcinoma pathogenesis Bo-Ying Bao - Anti-Cancer activity of Vitamin D in prostate cancer 2010 Emelian Scosyrev - The effect of neo-adjuvant platinum-based combination chemotherapy on pathological down-staging and survival of patients with locally advanced bladder cancer


2017 Carlos Ortiz-Bonilla – Extracellular vesicles as a possible mechanism for Bacillus Calmette-Guérin immunotherapy for bladder cancer.

Chia-Hao Wu - The Paradoxical Role of Extracellular Vesicles in Cancer Etiology

Mentoring

William Flesher, MS Jennifer Griggs, MD, MS Kate Wright, PhD Xi Na, MD, PhD Zaibo Li, MD, PhD Dakun Wang, MD Xiangrong He Aimee Johnson Bo-Ying Bao Emil Scosyrev Shin-Jen Lin

BIBLIOGRAPHY

JOURNAL PUBLICATIONS 1. Messing EM, Kessler R, Kavaney PB. Renal arteriovenous fistulas. Urology. 1976; 8:101-107. 2. Messing EM, Stamey TA. Interstitial cystitis: early diagnosis, pathology and treatment. Urology. 1978;

12:381-392. 3. Messing EM, Freiha FS. Complications of clorpactin in WCS-90 instillation. Urology. 1979; 13:389-392. 4. Messing EM, Henry SC. Stones in Orthotopic, non-obstructing Ureteroceles. J Urol. 1979; 122:403-405. 5. Freiha FS, Messing EM, Gross CM. Emphysematous pyelonephritis. J Contin Educ Urol. 1979; June: 9-

19. 6. Messing EM, Tarsin M. Fluorescent antibody coating of bacteria persisting in ureteral stump ten years

after nephrectomy. J Urol. 1981; 126:406-408. 7. Messing EM, deKernion JB. Adjuvant therapy in urologic cancer. Surg Clin North Am. 1981; 61:1331-

1345. 8. Messing EM, Fahey JL, deKernion JB, Bhuta SM, Bubbers JE. Serum free defined medium for the in vitro

growth of normal and malignant urinary bladder epithelial cells. Cancer Res. 1982; 42:2392-2397. 9. Messing EM, Bubbers JE, deKernion JB, Fahey JL. Growth stimulating activity produced by human

bladder cancer cells. Surg Forum. 1983; 34:683-687.


10. Messing EM, Bubbers JE, Whitmore KE, Nestor M, deKernion JB, Fahey JL. Murine hybridoma antibodies against human transitional cell carcinoma-associated antigens. J Urol (Investigative Urology). 1984; 132:167-173.

11. Messing EM. Transforming growth factor from human bladder cancer. Surg Forum. 1984; 35:662-664. 12. Messing EM, Bubbers JE, deKernion JB, Fahey JL. Growth factors produced by bladder cancer. J Urol

(Investigative Urology). 1984; 132:1230-1235. 13. Mohs F, Snow SN, Messing EM, Kuglitsch MD. Chemosurgery for squamous cell carcinoma of the penis.

J Urol. 1985; 133:961-966. 14. Schmidt WW, Messing EM, Reznikoff C. Cultures of normal human urothelial cells from ureters of

perfused cadaver transplant kidneys. J Urol (Investigative Urology). 1984; 132:1262-1265. 15. Roach R, Messing EM, Starling JR. Spontaneous thrombosis of spermatic veins. J Urol. 1985; 134:369-

370. 16. Messing EM, Dibbell DG, Belzer FO. Bilateral rectus Femoris pedicle flaps for detrusor augmentation in

the prune belly syndrome. J Urol. 1985; 134:1202. 17. Messing EM, Hanson P, Waters P. Ornithine decarboxylase activity and polyamine requirements of human

bladder cancer. Surg Forum. 1985; 36:651. 18. Fisher DT, Messing EM, Bruskewitz RC, Dibbell DG. Prevention of postoperative urinary diversion leaks

by use of loop double lumen drainage system. Urology. 1986; 27:553.

19. Messing EM, Love RD, Kvols L. Lymphoceles after retroperitoneal dissection for testes tumors. Cancer. 1986; 57:871-874.

20. Rodriguez P, Hafez GH, Messing EM. Non-seminomatous germ cell tumor of the testicle: does extensive

staging of the primary tumor predict the likelihood of metastatic disease? J Urol. 1986; 136:604-608. 21. Messing EM, Reznikoff CA. Normal and malignant human urothelial cells: response to epidermal growth

factor and ornithine decarboxylase blockade. Surg Forum. 1986; 37:661-664. 22. Durzinsky D, Messing EM, Myerowitz PD, Pellet J, Wilson M. A new method for assuring the accuracy of

the site of bone biopsies using 99 Tc bone scan. Cancer. 1987; 59:723-725. 23. Messing EM, Young TB, Hunt VB, Emoto SE, Wehbie J. The significance of asymptomatic micro-

hematuria in men age fifty and over: findings of a home screening study using urinary dipsticks. J Urol. 1987; 137:919-922.

24. Messing EM, Reznikoff CA. Normal and malignant human Urothelium: in vitro effects of epidermal

growth factor. Cancer Res. 1987; 47:2230-2235. 25. Messing EM. Early stage bladder cancer. Wisc Med J. 1987; 86:14-17. 26. Messing EM. Diagnosis of interstitial cystitis. Urology. 1987; 29(suppl):4-7. 27. Messing EM, Hanson P, Ulrich P, Erturk E. Epidermal growth factor - interactions with normal and

malignant Urothelium: in vivo and in situ studies. J Urol. 1987; 128:1329-1335.


28. Babel SG, McDermott JC, Goldrath DE, Crummy AB, Messing EM. Case report and review of the literature: uretero-arterial fistula after balloon dilatation and stent placement. J Interven Radiol. 1988; 3:135-138.

29. Messing EM, Hanson P, Reznikoff CA. Normal and malignant human Urothelium: in vitro response to

blockade of polyamine synthesis and interconversion. Cancer Res. 1988; 48:357-361. 30. Messing EM, Young TB, Hunt VB, Rust P, Wehbie JM. Urinary tract cancers found by home screening

with hematuria dipsticks in healthy men over 50 years of age. Cancer. 1989; 64:2361-2367. 31. Goldrath D, Messing EM. Prostate specific antigen: not detectable despite tumor progression after radical

prostatectomy. J Urol. 1989; 142:1082-1084. 32. Messing EM. Epidermal growth factor and bladder cancer: effects of urinary pH. Surg Forum. 1989;

40:694-696. 33. Trump DL, Havlin K, Messing EM, Cummings KB, Lange PH, Jordan VC. High-dose ketoconazole in

advanced hormone--refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol. 1989; 7:1093-1098.

34. Malec JF, Romsaas EP, Messing EM, Cummings KB, Trump DL. Psychological and mood disturbances

associated with the diagnosis and treatment of testis cancer and other malignancies. J Clin Psychol. 1990; 46:551-557.

35. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human

transitional cell carcinoma. Cancer Res. 1990; 50:2530-2537. 36. Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med. 1990; 32:838-845. 37. Dreicer R, Messing EM, Loehrer PJ, Trump DL. Perioperative methotrexate, vinblastine, doxorubicin and

cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: An Eastern Cooperative Oncology Group pilot study. J Urol. 1990; 144:1123-1128.

38. Messing EM. A common surgical approach to the upper retro-peritoneum and renal hilum. Contemp Urol.

1991; 3:12-21. 39. Huland E, Huland H, Meier TH, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM,

Schmitz-Draeger BJ. Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. J Urol. 1991; 146:1631-1636.

40. Edelman GC, Sweet ME, Messing EM, Helgerson RB. Treatment of severe electrical burns of the genitalia

and perineum by early excision and grafting. J Int. Soc. Burn Inj. 1991; 17(6):506-509. 41. Briggs NC, Young TB, Gilchrist KW, Vaillancourt AM, Messing EM. Superficial bladder cancer: age as a

predictor for aggressive clinical course among men. Cancer. 1992; 69:1445-1451. 42. Messing EM, Young TB, Hunt VB, Roecker EB, Vaillancourt AM, Hisgen WI, Greenberg EB, Kuglitsch

ME, Wegenke JD. Home screening for hematuria: results of a multi-clinic study. J Urol. 1992; 148:289-292.

43. Ritter MA, Shanahan TG, Potts SA, Chappell RI, Messing EM, Kinsella TJ. Prostate-specific antigen

(PSA) as a predictor of radiotherapy response and of patterns of failure in localized prostate cancer. J Clin Oncol. 1992; 10:1208-1217.


44. Sidransky D, Messing EM. Molecular genetics and biochemical mechanisms in bladder cancer: oncogenes, tumor suppressor genes, and growth factors. Urol Clin North Am. 1992; 19(4):629-640.

45. Pink JC, Messing EM, Reznikoff CA, Bryan GT, Swaminathan S. Correlation between N-acetyltransferase

activities in uroepithelium and in vivo acetylator phenotype. Drug Metab Dispos. 1992; 20:559-565. 46. Messing EM, Reznikoff CA. Epidermal growth factor and its receptor: markers of - and targets for -

chemoprevention of bladder cancer. J Cell Biochem. 1992; 161:56-62. 47. Messing EM. Growth factors and bladder cancer: clinical implications of the interactions between growth

factors and their urothelial receptors. Semin Surg Oncol. 1992; 8:285-292. 48. Loprinzi CL, Messing EM. A prospective clinical trial of Difluormethylornithine (DFMO) in patients with

resected superficial bladder cancer. J Cell Biochem. 1992; 161:153-155. 49. Waples MI, Messing EM. Redo retroperitoneal lymphadenectomy for germ cell tumor. Urology. 1993;

42:31-34. 50. Phillips E, Messing EM. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology.

1993; 41:9-15. 51. Reznikoff CA, Kao C, Messing EM, Newton M, Swaminathan S. A molecular genetic model of human

bladder carcinogenesis. Semin Cancer Biol. 1993; 4:143-152. 52. Sollinger HW, Messing EM, Eckhoff DE, Pirsch JD, D'Alessandro AM, Kalayoglu M, Knechtle SJ, Hickey

D, Belzer FO. Urological complications in 210 consecutive simultaneous pancreas-kidney transplants with bladder drainage. Ann Surg. 1993; 218:561-570.

53. Frederickson SM, Messing EM, Reznikoff CA, Swaminathan S. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase (NAT) and O-acetyltransferase (OAT) activities in human uroepithelial cells. Cancer Epidemiol, Biomarkers Prev. 1994; 3:25-32.

54. Messing EM, Murphy-Brooks N. Recovery of epidermal growth factor in voided urine of patients with

bladder cancer. Urology. 1994; 44:502-506. 55. Jønler M, Messing EM. Detection, diagnosis, and natural history of bladder cancer. Curr Opin Urol.

1994; 4:269-274. 56. Jønler M, Ritter MA, Brinkmann R, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of definitive

radiation therapy for prostate cancer localized to the pelvis. Urology. 1994; 44:876-882. 57. Jønler M, Rhodes P, Messing EM, Bruskewitz RC. Sequelae of radical prostatectomy. Br J Urol. 1994;

74:352-358. 58. Kloth MT, Gee RL, Messing EM, Swaminathan S. Expression of N-acetyltransferase (NAT) in cultured

human uroepithelial cells. Carcinogenesis 1994; 15:2781-2787. 59. Glazier DB, Bahnson RR, McLeod DG, von Roemeling RW, Messing EM, Ernstoff MS. Intravesical

recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J Urol. 1995; 154:66-68.

60. Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther

M, Fisher HAG, Messing E, Crawford ED, Oliff AI, Pastan IH. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clinical Cancer Res. 1995; 1:57-61.


61. Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, Hisgen WJ, Greenberg EB,

Kuglitsch ME, Wegenke JD. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995; 45:387-397.

62. Messing EM, Young TB, Hunt VB, Newton MA, Bram LL, Vaillancourt AM, Hisgen WJ, Greenberg EB,

Kuglitsch ME, Wegenke JD. Hematuria home screening: repeat testing results. J Urol. 1995; 154:57-61. 63. Tomic S, Warner TF, Messing EM, Wilding G. Penile Merkel Cell Carcinoma. Urology. 1995; 45:1062-

1065. 64. D'Alessandro AM, Solinger HW, Knechtle SJ, Kalayoglu M, Kisken WA, Uehling DT, Moon TD, Messing

EM, Bruskewitz RC, Pirsch JD, Belzer FO. Living Related and Unrelated Donors for Kidney Transplantation. A 28-year experience. Annals of Surg. 1995; 3:353-364.

65. Howard SP, Groch KM, Lindstrom MJ, Messing EM, Gould MN. Proliferation- independent growth factor

modulation of the radiation sensitivity of human prostate cells. Radiat Res. 1995; 143:229-233. 66. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA, Messing EM, et al.:

Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and Mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A southwest oncology group study. Urol Oncol. 1995; 1:119-126.

67. Lawrence WF, Bram LL, Messing EM. The Cost-Effectiveness of Screening Men for Bladder Cancer

Using Chemical Reagent Strips to Detect Microscopic Hematuria. J Urology. 1995; 153:477A. 68. Loprinzi CL, Messing EM, O'Fallon JR, Poon MA, Love RR, Quella SK, Trump DL, Morton RF, Novotny

P. Toxicity evaluation of Difluormethylornithine (DFMO): doses for chemoprevention trials. Cancer Epi Biomarkers. 1996; 5:371-374.

69. deVere White RW, Deitch AA, Tesluk H, Blumenstein B, Lowe BA, Sagalowsky AI, Smith, JA,

Schellhammer PF, Stanisic TH, Grossman HB, Messing EM. Prognostic Significance of DNA Ploidy in Ta/T1 Bladder Cancer. Urol Oncol. 1996; 2:27-34.

70. Wu SQ, Hafez GR, Xing W, Newton M, Chen XR, Messing EM. Chromosome 14q Loss in Non-papillary

Renal Cell Carcinoma Correlation with Histopathologic Grade, Clinical Stage and Outcome. Cancer. 1996; 77:1154-1160.

71. Kryger JV, Messing EM. Bladder Cancer Screening. Seminars in Oncology. Vol. 23, No. 5, October

1996; p. 585-597. 72. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM,

Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang NJ, Hayden CL. Urinary Nuclear Matrix Protein (NMP22) as a Marker for Transitional Cell Carcinoma of the Urinary Tract. J. Urol. 1996; 156:1280-1285.

73. Messing EM. Early Detection and Management of Prostate Cancer, Is it beneficial. Guthrie Journal. 1996;

65/3:114-119. 74. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing EM,

Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Uro. 1996; 156:363-367.


75. Jonler M, Madsen FA, Rhodes PR, Sall M, Messing EM, Bruskewitz RC. A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Urology. 1996; 48/3:433-440.

76. Reeder JE, Morreale JF, O’Connell MJ, Stadler WM, Messing EM, Wheeless LL. Loss of the

CDKN2A/p16 locus detected in bladder irrigation specimens by fluorescence in situ hybridization. Journal of Urology. 1997; 158:1717-1721.

77. Sall M, Madsen FA, Rhodes PR, Jonler M, Messing EM, Bruskewitz RC. Pelvic Pain following Radical

Retropubic Prostatectomy: A Prospective Study. Urology 49:575-579, 1997. 78. Joseph JV, Messing EM. Chemoprevention of Bladder and Prostate Carcinoma. Cancer Control.

March/April Vol. 4, No. 2, 1997. 79. Buzzeo, BD, Heisey DM, Messing EM. Bladder Cancer in Renal Transplant Recipients. Urology. 1997;

50/4:001-004. 80. Messing EM, Pauk D, Schaeffer A, Nieweglowski M, Nyberg LM, Landis R, Cook LM, Simon LJ.

Associations Among Cystoscopic Findings and Symptoms and Physical Examination Findings in Women Enrolled in the Interstitial Cystitis Data Base (ICDB) Study. Urology. 1997; 49:5A, 81-85.

81. Kozlowski P, Messing EM. Bladder Cancer Screening. Family Urology, 1997:16-18. 82. Reeder JE, O’Connell MJ, Yang Z, Morreale JF, Collins L, Frank IN, Messing EM, Cockett ATK, Cox C,

Robinson RD, Wheeless LL. DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients. Urology. 1998:51/5A; 58-61.

83. Goldstein M, Messing EM. Screening for Prostate and Bladder Cancer. J. Amer. College of Surgeons. 1998; 186:1, 63-74.

84. Stewart J, Kozlowski P, Sowden M, Messing EM, Smith HC. A Quantitative assay for assessing allelic

proportions by iterative gap ligation. Nucleic Acids Research. 1998; 26:4,961-966. 85. Jepsen JV, Mogens S, Rhodes PR, Schmidt D, Messing EM, Bruskewitz RC. Long-term experience with

pentosanpolysulfate in interstitial cystitis. Urology. 1998; 51:3,381-387. 86. Pan HJ, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, Chang C. Evaluation of RU58841 as an Anti-

Androgen in Prostate PC3 Cells and a Topical Anti-Alopecia Agent in the Bald Scalp of Stumptailed Macaques. Endocrine. 1998; 9:1, 39-43.

87. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. 5 Androstenediol is a Natural Hormone with

Androgenic Activity in Human Prostate Cancer Cells. Proc. Nat. Acad. Science. 1998; 95:11083-11088. 88. Yu Y, Zhang JB, Brasacchio R, Okunieff P, Rubens D, Strang J, Soni A, Messing E. Automated Treatment

Planning Engine for Prostate Seed Implant Brachytherapy. Int J Rad Onc. 1998; 43:1-7. 89. Messing EM, Zhang JB, Rubens DJ, Brasacchio RA, Strang JG, Soni A, Schell MC, Okunieff PG, Yu Y.

Intraoperative Optimized Planning for Prostate Seed Implant: Early Experience. Int J Rad Onc, Bio, Phys. 1999; 44/4:801-808.

90. Jung I, Reeder JE, Cox C, Siddiqui JFM, O’Connell MJ, Collins L, Yang Z, Messing EM, Wheeless LL.

Chromosome 9 Monosomy by Fluorescence in Situ Hybridization of Bladder Irrigation Specimens is Predictive of Tumor Recurrence. Journal of Urology, 1999; 162(6):1900-3.


91. Messing EM, Manola J, Sarosdy M, Trump D, Wilding G, Kiernan M, Crawford ED. Immediate Hormonal Therapy vs Observations in Men with Node Positive Prostate Cancer following Radical Prostatectomy and Pelvic Lymphadenectomy: A Randomized Phase III Eastern Cooperative Oncology Group/Intergroup Trial. NEJM, 1999:341:24; 1781-1788.

92. Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplum M, Simsiman R, Wilding G. Low-

dose Difluoromethylornithine and Polyamine Levels in Human Prostate Tissue. JNCI. 1999; 91:16; 1416. 93. Ochal LK, Sowden MP, Messing EM, Wheeless LL, Reeder JE. Mus musculus DBCCR1 mRNA,

complete sequence GenBank Accession AF202896, 1999. 94. Gottlieb RH, Zusman E, Hartley DF, Rubens DJ, Voci SL, Robinette W, Melendez L, Morris TW, Ojha S,

Chengazi V, Erturk E, Messing EM. Effect of angiotensin converting enzyme inhibition on the doppler waveform in dogs with renal artery stenosis. J Ultrasound Medicine 18:481-487, 1999.

95. deVereWhite RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA,

Schellhammer PF, Stanisic TH, Grossman HB, Messing EM, Crissman JD, Crawford ED. The Prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer: A Southwest Oncology Group Study. European Urology, 37(5):595-600, 2000.

96. Messing, EM. Early hormonal therapy in prostate cancer. (Editorial) NEJM; 2000:342:1216. 97. Jung I, Messing EM. Molecular Mechanisms, and pathways in bladder cancer development and

progression. Cancer Control 2000, 7:4; 325-334. 98. Mantalaris A, Panoskaltsis N, Sakai Y, Bourne C, Chang C, Messing E, Wu PhD. Localization of

androgen receptor expression in human bone marrow. J Path., 2001, 193:361-366. 99. Eichel L, Messing E. The timing of hormonal treatment for prostate cancer. Current Opinion in Urology,

10:403-407, 2000. 100. Wood R, Eichel L, Messing E, Schwarz E. Automated non-invasive measurement of

cyclophosphamide-induced changes in murine micturition frequency and volume. J Urol. 165:653-659, 2001.

101. Strang J, Rubens DJ, Brasacchio R, Yu Y, Messing EM. Real-time US versus CT determination of

pubic arch interference for brachytherapy. Radiology 219 387-393, 2001.

102. Eichel L, Scheidweiler K, Kost J, Shojaie J, Schwarz E, Messing E, Wood R. Assessment of

murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine. Urology 2001; 58(1):113-118.

103. Brawer MK, Stamey TA, Fowler J, Droller M, Messing E, Fair WR. Perspectives on prostate

cancer diagnosis and treatment: a roundtable. Urology 2001; 58 (2):135-140. 104. Sessions A, Messing E. Timing of hormonal therapy in prostate cancer. Urol Clin N America 29

(2002), 223-227. 105. Gottlieb RH, La TC, Erturk E, Sotack JL, Voci S, Holloway RG, Syed L, Mikityanski I, Tirkes AT,

Elmarzousky R, Zwemer FL, Schneider SM, Joseph JV, Davis D, DiGrazio WJ, Messing EM. CT in detecting urinary tract calculi: Influence on patient imaging and clinical outcomes. Radiology 225:441-449, 2002.


106. Li Z, Na X, Wang D, Schoen S, Messing EM, Wu G. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. Journal of Biol Chem. 2002:277(7):4656-4662.

107. Fisher TL, Nocera M, Willis RA, Turner MJ, Alim CS, Brown DM, Bourne PA, diSant'Agnese PA,

Messing EM, Lord EM, Frelinger JG. Generation of monoclonal antibodies specific for human kallikrein (hK2) using hK2-expressing tumors. The Prostate 9999:1-13, 2002.

108. Sessions A, Eichel L, Kassahun M, Messing EM, Schwarz E, Wood R. Continuous bladder

infusion methods for studying voiding function in the ambulatory mouse. Urology 2002; 60:707. 109. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. Identification of a deubiquitinating

enzyme as substrates of the von Hippel-Lindau tumor suppressor. Biochem, Biophys Res Commun. 294:700-709, 2002.

110. Wang D, Li Z, Messing EM, Wu G. Activation of Ras/Erk pathway by a novel MET-interacting

protein RanBPM. Journal of Bio Chemistry. 2002; 277(39):36216-22. 111. Lee YF, Lin WJ, Huang J, Messing EM, Chang F, Chang C. Non-androgen receptor mediated

antiandrogens action: Activation of MAP kinase pathway by hydroxyflutamide in androgen receptor negative prostate cancer cells. Cancer Research. 2002; 21:6039-6044.

112. Zhang Y, Ni J, Messing EM, Chang E, Yang CY, Yeh S. Vitamin E succinate inhibits the function

of androgen receptor and the expression of prostate specific antigen in prostate cancer cells. Proc Natl Acad Science. 2002; 99(11):7408-7413.

113. Liu H, Cheng G, Rubens D, Strang J, Liao R, Brasacchio R, Messing EM, Yu Y. Automatic

segmentation of prostate boundaries in transrectal ultrasound (TRUS) imaging. Proc SPIE. 2002; 4684:412-423.

114. Wright KO, Messing EM, Reeder JE. Increased expression of acid sphingomyelinase like protein,

ASML3a in bladder tumors. J Urol. 168:2645-2649, 2002. 115. Yu Y, Liu H, Cheng G, Rubens D, Strang J, Liao L, Brasacchio R, Messing E. An ultrasound-

based seed detection method for dynamic brachytherapy of the prostate. Medical Physics. 2002:29(6) - abstract.

116. Lee YF, Lin WJ, Huang J, Messing EM, Chang FL, Wilding G, Chang, C. Activation of mitogen-

activated protein kinase pathway by the antiandrogens hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Research 62(21):6039-44, 2002.

117. Na X, Wu G, Ryan CK, Schoen SR, di'SantAgnese PA, Messing EM. Over production of

vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1a expression of renal cell carcinoma. J Urol. 170:588-592, 2003.

118. Messing E, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes J, Hahn R, Trump D.

Phase III study of interferon alfa-nl (Wellferon) as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial. J Clin Oncol 21:1214-1222, 2003.

119. Reeder JE, Sowden MP, Messing EM, Klover P, Villa-Moruzzi E, Ludlow J. Inducible expression of

catalytically active type I serine/threonine protein phosphatase in a human carcinoma cell line. Cancer Cell International. 3:12, 2003.

120. Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan

R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM, ICCTG.


A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 170; 810-815, 2003.

121. Messing EM, Thompson I. Follow-up of conservatively managed prostate cancer watchful

waiting and primary hormonal therapy. Urol Clin NA. 30:687-702, 2003.

122. Borhan A, Reeder JE, O'Connell MJ, Wright KO, Wheeless LL, diSant'Agenese PA, McNally ML, Messing EM. Grade progression and regression in recurrent urothelial cancer. J Urol 169:2106-2109, 2003.

123. Messing, E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol Oncol. 21(4):245-54, 2003.

124. Na X, Duan Ho, Messing EM, Schoen SR, Ryan CK, diSant’Agnese PA, Golemis EA, Wu, G.

Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von-Hippel Lindau protein. EMBO Journal. 22(16):4249-59, 2003.

125. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu. The VHL protein recruits a novel KRAB-A

domain protein to repress HIF-1 alpha transcriptional activity. EMBO Journal. 22(8):1857-67, 2003.

126. Liu H, Cheng G, Yu Y, Brasacchio R, Rubens D, Strang J, Liao L, Messing EM. Automatic

localization of implanted seeds from postimplant CT images. Phy. Med. Biol. 48 1191-1203, 2003.

127. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004 Jan 1; 58(1):3-10.

128. Rashid HH, Reeder JE, O’Connell MJ, Zhang C, Messing EM, Keay SK. Interstitial cystitis anti-

proliferative factor (APF) as a cell-cycle modulator. BMC Urology 41(1):3, 2004.

129. Leung YYM, Schwarz EM, Silvers CR, Messing EM, Wood RW. Uroflow in murine urethritis. Urology. 64:378-382, 2004.

130. Madeb R, Messing EM. Gender, Racial and Age Differences in Bladder Cancer Incidence and Mortality. Urologic Oncology: Sem and Original Invest. 22:86-92, 2004.

131. Wright KO, Messing EM, Reeder JE. DBCCR1 mediates death in cultured bladder tumor cells. Oncogene. 23(1):82-90, 2004.

132. Wang D, Li Z, Schoen S, Messing EM, Wu, G. A novel MET-interacting protein shares high

sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling. Biochem, Biophys Res Comm. 313(2):320-6, 2004.

133. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. The Prostate. 61(4):332-53, 2004.

134. Miyamoto H, Messing EM. Early versus late hormonal therapy for prostate cancer. Current Urology Reports. 5:188-196, 2004.

135. Li Z, Wang D, Messing EM, Wu G. The VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. EMBO Reports 6(4):373-8, 2005.

136. Wang D, Li Z, Messing EM, Wu G. The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the HGF-induced Erk-Elk-1-SRE pathway. J Biol Chem. 280(16):16393-401, 2005.

137. Grossman HB, Messing EM, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293:810-816.


138. Miyamoto H, Messing EM, Chang C: Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nature Clinical Practice Oncology 2: 236-237, 2005.

139. Taylor LS, Rubens DJ, Porter BC, Wu Z, Baggs R, diSant’Agnese PA, Nadasy G, Pasternack D, Messing EM, Nigwekar P, Parker K. Three-dimensional sonoelastography for in-vitro detection of prostate cancer. Radiology 237(3):981-5, 2005.

140. Fu L, Ng WS, Liu H, O’Dell W, Ruben D, Strang J, Schell MC, Brasacchio R, Liao L, Messing EM, Yu Y. Bouquet brachytherapy: Feasibility and optimization of conically spaced implants. Brachytherapy (4), 59 – 63, 2005.

141. Podder TK, Sherman J, Clark DP, Messing EM, Rubens DJ, Strang JG, Liao L, Ng WS, Zhang YD, Yu Y. Method to reduce force and target movement during surgical needle interventions. European Medical & Biol Engineer. 11:4315-4320, 2005.

142. Podder TK, Clark DP, Fuller D, Messing EM, Rubens DJ, Strang JG, O’Dell W, Zhang YD, Ng WS, Yu Y. Effects of tip geometry of surgical needles: An assessment of force-torque and deflection. European Medical & Biol Engineer. 11:1641-1644, 2005.

143. Messing EM, Teot L, Korman H, Underhill J, Barker E, Stork B, Qian J, Bostwick DG. Performance of Urine Test in Patients Monitored for Recurrence of Bladder Cancer: A Multi-Center Study in the United States. J Urol 2005; 174:1238-1241.

144. Lokeshwar, V.B., Habuchi, T., Grossman, H.B., Murphy, W.M., Hatumann, S.H.,Hemstreet III, G.P., Bono, A.V., Getzenberg, R.H., Goebell, P., Schmitz-Drager, B.J., Schalken, J.A., Fradet, Y., Marberger, M., Messing, E., and Droller, M.JBladder tumor markers beyond cytology: Bladder Cancer Consensus Panel. Urology 2005; 66:35-63.

145. Habuchi, T., Marberger, M., Droller, M.J., Hemstreet III, G.P., Grossman, H.B., Schalken, J.A., Schmitz-Drager, B. J., Murphy, W.M., Bono, A.V., Goebell, P., Getzenberg, R.H., Hautmann, S.H., Messing, E., Fradet, Y., Lokeshwar, V.B.* Prognostic marker for bladder cancer: Bladder Cancer Consensus Panel. Urology 2005; 66:64-74.

146. Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C. Inhibition of the Akt, Cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinogenesis 44:1-10, 2005.

147. Grossman HB, Soloway M, Messing EM, Katx G, Stein B, Kassabian V, Shen Y. Surveillance of patients with a history of bladder cancer using a point-of-care proteomic assay. JAMA 295(3):299-305, 2006.

148. Johnson AM, Conover DL, Huang J, Messing EM, Ning R, O’Connell MJ, Rossi MA, Sun TT, Wood RW, Wu XR, Reeder JE. Early detection and measurement of urothelial tumors in mice. Urology 67(6):1309-14, 2006...

149. Bockzo J, Messing EM, Dogra V. Prostate sonography. Radiology Clin N Am. 44(4); 2006.

150. L. Fu, H. Liu, W. S. Ng, D. Rubens, J. Strang, E. Messing, Y. Yu (2006). Hybrid dosimetry: Feasibility of mixing angulated and parallel needles in planning prostate brachytherapy. Med. Phys. 33 1192-1198.

151. Messing EM. Bladder Tumor Markers. Editorial Reply. J Urol 175(4):1195-6; 2006.

152. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, diSant’Agnese PA, Trump D. Immediate vs delayed androgen deprivation therapy in patients with node positive prostate cancer who had undergone radical prostatectomy + pelvic lymphadenectomy: Results of Central Pathology Review: Eastern Cooperative Oncology Group Study EST3886. Lancet Oncology, 7(6):472-9; 2006.

153. Wood RW, Baggs RB, Schwarz EM, Messing EM. Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate. Urology 67:1324-1328, 2006.


154. V. Misic, L. Fu, T.K. Podder, L. Liao, D.J. Rubens, R. Brasacchio, E.M. Messing, J.G. Strang, W.S. Ng, and Y. Yu. Dynamic planning in single needle brachytherapy systems. Int. J. CARS (2006) 1:265-292 271 – 273.

155. T.K. Podder, L. Liao, J. Sherman, D. Fuller, V. Misic, D.J. Rubens, E.M. Messing, J.G. Strang, W.S. Ng, and Y. Yu. A method to minimize puncture force and organ deformation. Int. J. CARS (2006) 1:265-292 277 – 280.

156. T.K. Podder, D. P. Clark, J. Sherman, D. Fuller, E. M. Messing, D. J. Rubens, J. G. Strang, R. A. Brasacchio, L. Liao, W. S. Ng, and Y. Yu, “In vivo Motion and Force Measurement of Surgical Needle Intervention during Prostate Brachytherapy,” in the Medical Physics Journal, Vol. 3, No. 8, pp. 2915-2922, August 2006.

157. T.K. Podder, J. Sherman, D. Fuller, E.M. Messing, D.J. Rubens, J.G. Strang, R.A. Brasacchio, and Y. Yu, “Needle Insertion Force Estimation Model using Procedure-specific and Patient-specific Criteria,” in the Proceedings of the 28th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS/EMBC), pp. 555-558, New York, NY, Aug. 31 – Sept. 3, 2006.

158. T.K. Podder, J. Sherman, D. Fuller, E.M. Messing, D.J. Rubens, J.G. Strang, R.A. Brasacchio, and Y. Yu, “Surgical Needle Intervention in Soft Tissue: In-vivo Force Measurement,” in the Proceedings of the 28th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS/EMBC), New York, NY, pp. 3652-3655, Aug. 31 – Sept. 3, 2006.

159. J. Sherman, T.K. Podder, L. Fu, V. Misic, D. Fuller, B. Winey, E.M. Messing, D.J. Rubens, J.G. Strang, R. A. Brasacchio, and Y. Yu, “Efficacy of Prostate Stabilizing Techniques during Brachytherapy Procedure,” in the Proceedings of the 28th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS/EMBC), pp. 563-566, New York, NY, Aug. 31 – Sept. 3, 2006.

160. Messing EM, Kim K, Sharkey F, Schultz M, Parnes H, Kim D, et al. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 2006; 176:500-504.

161. Messing EMM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, Wegenke JD, Stephenson L, Gee J, Feng C. Long-term Outcome of Hematuria Home Screening for Bladder Cancer in Men. Cancer 2006; 107:2173-9.

162. Thompson I, Tangen C, Paradelo J, Lucia MS, Miller G, Troyer D, Messing EM, et al. Adjuvant radiotherapy for pathologically-advanced prostate cancer: Results of a randomized prospective clinical trial. JAMA 2006; 296:2329-2335.

163. Golijanin D, Kakiashvili D, Madeb R, Messing EM, Lerner S. Chemoprevention of bladder cancer. World J Urol 24(5):445-72, 2006.

164. Podder TK, Sherman J, L Li, Joseph J, Ruben DR, Messing EM, Huang J, Yu Y. Mechanical

properties of human prostate tissue in the context of surgical needle insertions. CARS, S106-108, 2007.

165. Madeb R, Golijanin D, Knopf J, Messing EM. Current state of screening for bladder cancer.

Expert Review of Anticancer Therapy. 7(7):981-7, 2007. 166. Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang Y-J,

Hu Y-C, Tsai M-Y, Yeh S, Messing EM, Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. JNCI 2007; 99:558-68.

167. Messing, EM. Micro-hematuria: Implications of an unexpected finding. Consultant. 47:356; 2007.


168. Swanson GP, Hussey MA, Tangen CAS, Chin J, Messing EM, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. Predominant treatment failure in post-prostatectomy patients is local: Analysis of Patterns of Treatment Failure in SWOG 8794. J Clin Onc 2007; 25:2225-2229.

169. Ting, H, Bao B, Reeder J, Messing EM, Lee Y. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1 alpha 25-dihydroxyvitamin D3 responsiveness. Mol Cancer Res 2007; 5(9); 967-980.

170. Yu, Y., Podder, T. K., Zhang, Y. D., Ng, W. S., Misic, V., Sherman, J., Fuller, D., Rubens, D. J., Strang, J. G., Brasacchio, R. A. and Messing, E. M. (2007) 'Robotic system for prostate brachytherapy', Computer Aided Surgery, 12:6, 366 – 370.

171. Messing EM, Madeb RM. Long-term outcome of dip-stick testing for hematuria. World Journal of Urology 26(1):19-24, 2008.

172. Tarun Podder, Jason Sherman, Deborah Rubens, Edward Messing, John Strang, Wan-Sing Ng and Yan Yu, "Methods for prostate stabilization during transperineal LDR brachytherapy", in the J. Physics in Medicine and Biology, vol. 53, pp. 1563-1579, February 2008.

173. Johnson AM, O’Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM. Reeder JE. Androgen dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: A role for thrombospondin-1. BMC Urology, 2008; 8:7.

174. Johnson AM. O’Connell, Messing EM. Reeder JE. Decreased bladder cancer growth in parous

mice. Urology 72(3):470-3, 2008. 175. Man Zhang, Priya Nigwekar, Benjamin Castaneda, Kenneth Hoyt, Jean V. Joseph, Anthony di

Sant'Agnese, Edward M. Messing, John G. Strang, Deborah J. Rubens and Kevin J. Parker. Quantitative Characterization of Viscoelastic Properties of Human Prostate Correlated with Histology, Ultrasound in Medicine & Biology, 2008; 34(7):1033-1042.

176. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke W, Messing EM, Yao J, Yeh S, Chang C. Androgen

receptor is a tumor suppressor and proliferator in prostate cancer. PNAS 2008:105; 12182-12187. 177. Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD,

Thompson IM, Crawford ED. The Prognostic Impact of Seminal Vesicle Involvement found at Prostatectomy and the Effects of Adjuvant radiation in those Patients: Data from SWOG 8794. J Urol 180:2453-7, 2008.

178. Singer E, Golijanin DJ, Messing EM. Androgen deprivation therapy for advanced prostate cancer:

Why does it fail and can its effects be prolonged? The Canadian J of Urology. 15(6):4381-4387, 2008.

179. Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate

cancer. Expert Opinion Pharmacotherapy. 9(2);211-28, 2008 180. Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, Nakada SY, Messing

EM. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacilli Calmette-Guerin. BJU Internat 2009; 103:736-9.

181. Noyes K, Singer EA, Messing EM. Healthcare economics of bladder cancer: Cost-enhancing and

cost-reducing factors. Current Opinion Urology 18(5):533-9, 2008 182. Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of

intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette Guerin (E3897): A trial of the Eastern Cooperative Oncology Group. Urol Oncology July 16, 2008.


183. Messing EM. Why should we increase public awareness of bladder cancer, and how can we do it? Nat Clin Pract Urology 5(3):117, 2008

184. Scosyrev E, Noyes K, Feng CY, Messing EMM. Sex and racial differences in bladder cancer

presentation and mortality in the United States. Cancer, 1; 115(1):68-74, 2009. 185. Chen M, Hsu I, Wolfer A, Radovick S, Huang K, Yu S, Chang C, Messing EM, Yeh S. Defects of

prostate development and reproductive system in the estrogen receptor-alpha null male mice. Endocrinology 150(1):251-9, 2009.

186. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J,

Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urology 181(3):956-962, 2009.

187. Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, Knopf J, Lyman G, Messing EM.

Treatment of Superficial Bladder Cancer: Do physicians in the United States Practice Evidence Based Medicine? The use and economic implications of Intravesical Chemotherapy after Transurethral Resection of Bladder Tumors. Cancer 2009; 115:2660-7

188. Messing EM, Madeb R, Feng CY, Stephenson L, Gilchrist KW, Young T, Gee J.Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease? JCO 2009; 27:2443-9.

189. Yan K, Li L, Joseph J, Rubens DR, Messing EM, Liao L, Yu Y. A real-time prostate cancer

detection technique using needle insertion force and patient-specific criteria during percutaneous intervention. Med Phys 2009; 36:3356-62.

190. Scosyrev E, Yao J, Messing EM. Urothelial carcinoma versus squamous cell carcinoma of the

bladder: Is survival different with stage adjustment? Urology 2009; 73:822-7. 191. Trivedi D, Messing EM. Commentary: The role of cytologic analysis of voided urine in the

work-up of asymptomatic micro-hematuria. BMC Urol 10:913; 2009.

192. Madeb R, Golijanin D, Knopf J, Davis M, Feng CY, Fender A, Stephenson L, Messing EM. Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology 75:20-26, 2010.

193. Scosyrev E, Trivedi D, Messing EM. Female bladder cancer: incidence, treatment, and outcome.

Current Opinion Urol 20:404-408, 2010. 194. Messing EM, Golijanin D, Knopf J, Madeb R. Re: Dipstick Pseudohematuria: Unnecessary

consultation and evaluation. J Urol 184 (3):1225, 2010. 195. Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O’Donnell MA, Reid

RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank Session 3: Prevention of bladder cancer. Urol Oncol 28:338-42; 2010.

196. Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y. BCAN Think Tank session

2: Molecular detection of bladder cancer: the path to progress. Urol Oncol 28(3):334-7; 2010. 197. Palapattu G, Singer EA, Messing EM. Controversies surrounding lymph node dissection for

prostate cancer. Urol Clin North America. 37(1):57-65; 2010.


198. Scosyrev E, Yao J, Messing EM. Microscopic invasion of perivesical fat by urothelial carcinoma: Implications for prognosis and pathology practice. Urology. 2010 Oct;76(4):908-13

199. Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A,

Sahsrabudhe D. Exploratory study of a KLK2 polymorphism as a prognostic marker in Prostate cancer. Cancer Biomark. 2010; 7(2):101-8.

200. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, deVereWhite RW,

Vogelzang NJ, Trump DL, Natale RB, Tangen C, Crawford ED, Thompson IM. Do mixed histologic features affect survival benefit from neo-adjuvant platinum-based combination therapy I in patients with locally advanced bladder cancer? BJU Int. 108:(5);693-9, 2011.

201. Bendana E, Trivedi D, Marshall J, Messing E. Lost and Now Found: Retained Straight Catheter

for 20 years”. Urology. 2011 Jan; 77(1):73-4.

202. He X, Wang J, Messing EM, Wu G. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I induced renal carcinoma cell invasiveness. Oncogene. 2011 Feb 3; 30(5):535-47.

203. Mir C, Shariat SF, Van Der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi

R, Kuk C, Alkhateeb S, Morote J, Van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011 July; 108(1): 24-30.

204. Purnell JQ, Palesh OG, Heckler CE, Adams MJ, Chin N, Mohile S, Peppone LJ, Atkins JN, Moore DF, Spiegel D, Messing E, Morrow GR. Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men. Support Care Cancer. 2011 July: 19(7): 899–907.

205. Lloyd G, Singh M, Messing EM. An Unusual Cause of an Enhancing Retroperitoneal Mass. Urology. Available online September 25, 2011. 206. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate Cancer in the Elderly:

Frequency of advanced disease at presentation and disease-specific mortality. Cancer. October 2011: [Epub ahead of print]: DOI: 10.1002/cncr.26392. 207. Ting, HJ, Yasmin-Karim S, Yan SJ, Hsu JW, Lin TH, Zeng W, Messing J, Sheu TJ, Bao BY, Li

W, Messing E, Lee YF. A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res; 72(4); 958-68.

208. Loberant N, Bhatt S, Messing E, Dogra VS. Bilateral testicular epidermoid cysts. J Clin Imaging Science. 2011; 1:4 Epub 2011. 209. Trivedi D, Messing EM. Words of Wisdom Re: Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical

Cystectomy: A High-Volume Tertiary Cancer Center Experience. Eur Urology, 2011; 59(2): 302- 303.

210. Scosyrev E, Messing EM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer. BJU Int. 2011 Sep; 108(5):700 211. Gordetsky J, Scosyrev E, Rashid H, Wu G, Silvers C, Golijanin D, Messing EM, Yao JL. Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens. Mod Pathol. January 2012: 25(1): 140-4.

http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20414685

http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=20414685


212. Scosyrev E, Messing EM, van Wijngaarden E, Peterson DR, Sahasrabudhe D, Golijanin D, and Fisher SG. Neo-adjuvant gemcitabine-cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer. January 2012: 118(1): 72-81. 213. Scosyrev E, Golijanin D, Wu G, Messing EM. The burden of bladder cancer in men and women: analysis of the years of life lost. BJU Int. January 2012: 109(1): 57-62. 214. Messing EM, Albertsen P, Andriole GL Jr, Carroll PR, Klein EA. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. Urol Oncol. 2012; Jan-Feb 30(1):117-9. 215. Ting, HJ, Yasmin-Karim S, Yan SJ, Hsu JW, Lin TH, Zeng W, Messing J, Sheu TJ, Bao BY, Li W, Messing E, Lee YF. A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res. 2012; Feb 15 72(4):958-68. 216. Scosyrev E, Messing J, Noyes K, Veazie P, Messing EM. Surveillance Epidemiology and End

Results (SEER) program and population-based research in urologic oncology: An overview. Urologic Oncology. March-April 2012: 30(2): 126-132.

217. Tobis S, Knopf J, Silvers C, Marshall J, Cardin A, Wood R, Reeder J, Erturk E, Madeb R,

Yao J, Singer E, Rashid H, Wu G, Messing E, Golijanin J. Near infrared fluorescence imaging following intravenous indocyanine green: Initial clinical experience with open partial nephrectomy for renal cortical tumors. Urology. 2012; April 79(4): 958-64.

218. Lloyd G, Singh M, Messing EM. An Unusual Cause of an Enhancing Retroperitoneal Mass. Urology. 2012; Apr; 79(4): e61-2.

219. Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S. Expression of androgen and estrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU International. 2012; June 109(11): 1716-26. 220. Tobis S, Venigalla S, Knopf JK, Scosyrev E, Golijanin D, Erturk E, Joseph JV, Rashid H, Wu GJ. Robot-assisted laparoscopic partial nephrectomy: review of the first 100 cases from a single institution. J Endourology. 2012; July 26(7): 797-802. 221. Byler TK, Leocadio D, Shapiro O, Bratslavsky G, Stodgell CJ, Wood RW, Messing EM, Reeder JE. Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol. 2012; August 16(12):21. 222. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate Cancer in the Elderly: Frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012; 118(12):3062-70. 223. Scosyrev E, Wu G, Golijanin D, Messing EM. Prostate-specific antigen testing in older men in the United States: data from the Behavioral Risk Factor Surveillance System. BJU Int. 2012; Nov 110(10): 1485-90 224. Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 2012; December 118(23): 5768-5776. 225. Davis R. Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, Messing EM, Miller SD, Peterson AC, Turk TM, Weitzel W. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012; (188): 2473-2481.


226. Baran TM, Wilson JD, Mitra S, Yao JL, Messing EM, Waldman DL, Foster TH. Optical property measurements establish the feasibility of photodynamic therapy as a minimally invasive intervention for tumors of the kidney. J Biomed Opt. 2012; 17(9):98002-1. 227. Messing E, Gee JR, Saltzstein DR, Kim K, Disant'agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H. A phase 2 cancer chemo prevention biomarker trial of isoflavone G-2535 (Genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila). 2012; 5(4): 621-630. 228. Messing EM. Words of wisdom. Re: Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Eur Urol. 2012; 62(5):935-6. 229. Knopf J, Messing E. Editorial Comment. Urology. 2012; 79(1): 171. 230. Scosyrev E, Wu G, Golijanin D, Messing EM. Non-bladder cancer mortality in patients with

urothelial cancer of the bladder. Urol Oncology. July 2013; 31(5):656-63. 231. Larre S, Catto J, Cookson M, Messing EM, Shariat S, Soloway M, Svatek R, Lotan Y, Zlotta A, Grossman HB. Screening for bladder cancer: rationale, limitations, whom to target and perspectives. European Urology, 2013; 63(6): 1049-58. 232. Shyr CR, Chen CC, Hsieh TF, Chang CH, Ma WL, Yeh S, Messing E, Li TH, Li FY, Chang C. The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells. Endocrine. 2013; 43(1):191-9. 233. Scosyrev E, Messing EM. Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer. 2013; 119(5): 1113-4. 234. Ghazi A, Scosyrev E, Patel H, Messing EM, Joseph JV. Complications associated with extraperitoneal robot-assisted radical prostatectomy using the standardized Martin classification. Urology. 2013; 81(2): 324-31. 235. Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H, Messing E. Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. BJU Int. 2013; 111(3 Pt B):E71-7. 236. Yang D, Lin S, Ding X, Miyamoto H, Messing EM, Li L, Wang N, Chang C. Higher expression of PPAR or its activation via an agonist TZD-rosiglitazone promotes bladder cancer cell migration and invasion. Urology. 2013; 81(5):1109. 237. Weight CJ, Miller DC, Campbell SC, Derweesh IH, Lane BR, Messing EM. The management of a clinical t1b renal tumor in the presence of a normal contralateral kidney. J Urol. 2013; 189(4): 1198-202. 238. Campbell SC, Derweesh IH, Lane BR, Messing EM. The management of a clinical T1b renal tumor in the presence of a normal contralateral kidney: The case for nephron-sparing surgery. J. Urology, 189; 2013. 239. Borch M, Scosyrev E, Baron B, Encarnacion J, Smith EM, Messing E. A randomized trial of 2% lidocaine gel versus plain lubricating gel for minimizing pain in men undergoing flexible cystoscopy. Urologic Nursing. 2013; 33(4).


240. Messing, EM. PSA screening for prostate cancer. Doctor’s Advice (Monroe County Medical Society). 2013.

241. Messing EM. N+M0 prostate cancer: local therapy for systemic disease. Oncology (Williston Park) 2013 Jul; 27(7): 661-2, 668.

242. Dogra VS, Chinni BK, Valluru KS, Joseph JV, Ghazi A, Yao JL, Evans K, Messing EM, Rao NA.

Multispectral photoacoustic imaging of prostate cancer: preliminary ex-vivo results. J Clin Imaging Sci. 2013 Sept. 30.

243. Zhang H, Messing EM, Travis LB, Hyrien O, Chen R, Milano MT, Chen Y. Age and racial

differences among PSA-detected (AJCC stage T1cN0M0) prostate cancer in the U.S.: a population-based study of 70,345 men. Frontiers in Oncology. 23 December 2013, Volume 3:312.

244. Hsu JW, Yin PN, Wood R, Messing J, Messing E, Lee YF. 1 alpha, 25-dihydroxylvitamin D3

promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer. Oncotarget 2013 4(12): 2397-2406.

245. Scosyrev E, Messing EM. Radical versus partial nephrectomy for a small renal mass: does saving nephrons save lives? Expert Reviews of Anticancer Therapy. 2013 Dec; 13(12):1349-51.

246. Donsky H, Coyle S, Scosyrev E, Messing EM. Sex differences in incidence and mortality of bladder and kidney cancers: National estimates from 49 countries. Urol Oncol. 2014; 32(1):40. 247. Dunne RF, Sahasrabudhe DM, Messing EM, Jean-Gilles J, Fung C. A case series of transformation of teratoma to primitive neuroectodermal tumor: evolving management of a rare malignancy. Rare Tumors. 2014 Mar 18; 6(1): 5208. 248. Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ. Survival of patients

undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted therapy era. Anticancer Research. 2014, (34): 2405-2412.

249. Scosyrev E, Wu K, Levey HR, Agrawal V, Beckham C, Wu G, Messing E. Overall survival after

partial versus radical nephrectomy for a small renal mass: systematic review of observational studies. Urology Practice. 2014, (1): 27-34.

250. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron- sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. European Urology. 2014 Feb; 65(2): 372-377. 251. Kolesar JM, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Kim K, Tangrea JA, Parnes HL, House MG, Gee J, Messing E, Bailey HH. Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract. 2014 Mar 17. 252. Slavin S, Yeh CR, Jun D, Yu S, Miyamoto H, Messing EM, Yeh S. Estrogen Receptor α in Cancer Associated Fibroblasts Suppresses Prostate Cancer Invasion via Modulation of Thrombospondin-2

and Matrix Metalloproteinase 3. Carcinogenesis. 2014 June; 35(6): 1301-9. 253. Messing EM. N+ M0 prostate cancer: local therapy for systemic disease. Oncology (Williston

Park). 2013 Jul; 27(7):661-2, 668. 254. Messing EM. Editorial Comment. Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis. J Urol. 2014 Jul 7. 255. Krabbe LM, Svatek RS, Shariat SF, Messing E, Lotan Y. Bladder cancer risk: use of the PLCO and NLST to identify a suitable screening cohort. Urol Oncol. 2014 Jul 16.

http://www.ncbi.nlm.nih.gov/pubmed/23831109


256. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder cancer think tank: collaborating to move research forward. Urol Oncol 2014 Jul 24. 257. Willis DK, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TN, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug; 32(6): 826-32. 258. Beckham C, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen F, Scosyrev E, Messing E,

Lee YF. Bladder Cancer Exosomes Contain EDIL-3/Del1 and Facilitate Cancer Progression. J of Urology. 2014 Aug; 192(2).

259. Fung C, Pandya C, Noyes K, Scosyrev E, Sahasrabudhe DM, Messing EM, Mohile SG. Impact of Bladder Cancer (BC) on Health-related Quality of Life (HRQL) in 1,476 Older Americans.

J Urol. 2014 Sep; 192(3): 690-5. 260. Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM,

Guancial EA, Yeh S. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway in vitro and in vivo. Oncotarget. 2014 Sep 15; 5(17): 7917-35.

261. Yasmin-Karim S, King MR< Messing EM, Lee YF. E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis. Oncotarget. 2014 Dec 15; 5(23): 12097-110.

262. Baack Kukreja J, Scosyrev E, Brasacchio RA, Toy EP, Messing EM, Wu G. Bladder cancer

incidence and mortality in patients treated with radiation for uterine cancer. BJUI. 2014; 114: 844-851.

263. Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, Mohile SG, Fung C. Bladder cancer in the elderly patient: challenges and solutions. Clinical Interventions in Aging 2015:10, 939-949. 264. Rojas KD, Montero ML, Yao JL, Messing EM, Fazili AA, Joseph J, Ou Y, Rubens D, Parker KJ, Davatzikos C, Castaneda B. Methodology to study the 3D spatial distribution of prostate cancer and their dependence on clinical parameters. J Med Imaging (Bellingham). 2015 Jul; 2(3):037502 265. Shang Z, Li Y, Zhang M, Tian J, Han R, Shyr CR, Messing E, Yeh S, Niu Y, Chang C. Anti- androgen therapy with Hydroxyflutamide or androgen receptor degradation enhancer ASC-J9® enhances BCG efficacy to better suppress bladder cancer progression. Mol Cancer Ther 2015 Aug 11; pii: molcanther.1055 266. Ptaszynska A, Cohen SM, Messing EM, Reilly TP, Johnsson E, Johnsson K. Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’. Springer Healthcare/inScience Communications. Diabetes Ther. 2015 Sep; 6(3):357-75. 267. Baack Kukreja JE, Levey HR, Scosyrev E, Kiernan M, Berrondo C, McNamee C, Wu G, Joseph JV, Ghazi A, Rashid H, Dozier A, Messing EM. Effectiveness and safety of extended duration prophylaxis for venous thromboembolism in major urologic oncology surgery. Urol Oncol. 2015 Sep; 33(9):387. 268. Kukreja JB, Messing EM. Editorial Comment. Urology. 2015 Nov; 86(5):972-3. doi: 10.1016/j.urology.2015.05.043. Epub 2015 Sep 26




269. Messing, EM. Bladder cancer. Paper Alert. 2016 Jan 28; 2(1):123-125. 270. Kilari D, Iczkowski KA, Pandya C, Robin AJ, Messing EM, Guancial E, Kim ES. Copper Transporter-CTR1 expression and pathological outcomes in platinum-treated muscle-invasive bladder cancer patients. Anticancer Res. 2016 Feb; 36(2):495-501. 271. Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF. Identification of extracellular vesicle periostin as a urinary biomarker of muscle invasive bladder cancer progression. Oncotarget. 2016; Apr 26; 7(17):23335-45. 272. Baack Kukreja JE, Messing EM, Shah JB. Are we doing “better”? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists. Urol Oncol. 2016 Mar; 34(3):120.e17-21. Doi: 10.1016/j.urolonc.2015.10.002. 273. Messing EM. Paper Alert. Bladder Cancer. 2016 Apr 27; 2 (2):283-284. 274. Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S. Targeting estrogen/estrogen receptor alpha will enhance Bacillus Calmette-Guerin efficacy in bladder cancer. Oncotarget. 2016; 7(10):27325-35 doi: 10.18632/oncotarget.8756. 275. Ramirez D, Gupta A, Canter D, Harrow B, Dobbs RW, Kucherov V, Mueller E, Streeper N, Uhlman MA, Svatek RS, Messing EM, Lotan Y. Microscopic hematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. BJU Int. 2016; 117(5):783-6. 276. Guancial EA, Kilari D, Xiao G-Q, Abu-Farsakh SH, Baran A, Messing EM, Kim ES. Platinum concentration and pathologic response to cisplatin-based neoadjuvant chemotherapy in muscle- invasive bladder cancer. PLoS One. 2016 May 17; 11(5): e0155503. doi:0.1371/journal.pone.0155503. 277. Messing EM. Editorial Comment. Risk factors and microbial distribution of urinary tract infections following radical cystectomy. Urology. 2016 May 20. pii: S0090-4295(16)30118-2 278. Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH. Phase Ib placebo-controlled, tissue biomarker trial of Diindolylmethane (BR_DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Eur J Cancer Prev. 2016 Jul; 25(4):312-20 279. Meng Y, Levey Bernie H, Guancial E, Messing EM. Complete remission of locally advanced penile squamous cell carcinoma after multimodality treatment: a report of two cases and literature review. Rare Tumors. 2016; 8(4):6651. 280. Scosyrev E, Messing EM, Sylvester R, Van Poppel H. Exploratory subgroup analyses of renal function and overall survival in European Organization for Research and Treatment of Cancer randomized trial of nephron-sparing surgery versus radical nephrectomy. Eur Urol Focus 2017; 3(6):599-605. 281. Horovitz D, Lu X, Feng C, Messing EM, Joseph JV. Rate of Symptomatic Lymphocele Formation After Exraperitoneal vs. Transperitoneal Robot Assisted Radical Prostatectomy and Bilateral Pelvic Lymphadenectomy. J Endourology 2017; 31(10):1037-1043. 282. Messing, EM. Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. Eur Urol. 2017 Mar 11. pii: S0302-2838(17)30130-6








283. Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric MRI: Correlation With final Histopathology. J Urol. 2017; 198(2):316-321. 284. Messing EM. A More Thorough Transurethral Resection. Bladder Cancer. 2017 Jan 27; 3(1): 75-77. 285. Messing EM. Bladder Sparing Therapy for BCG Failures – Intravesical Immunotherapy. Bladder Cancer 2017; 3(4):313-314. 286. Horovitz D, Feng C, Messing EM, Joseph JV. Exraperitoneal vs Transperitoneal robot-assisted radical Prostatectomy in patients with a history of prior inguinal hernia repair with mesh.

J Robot Surg. 2017; 11(4)447-454. doi: 10.1007/s11701-017-0678-0. 287. Horovitz D, Feng C, Messing EM, Joseph JV. Exraperitoneal vs. Transperitoneal Robot-Assisted

Radical Prostatectomy in the Setting of Prior Abdominal or Pelvic Surgery. J Endourol. 2017; 31(4):366-373. doi: 10.1089/end.2016.0706.

288. Messing EM. Checkpoint Inhibitors for Advance Bladder Cancer. Bladder Cancer. 2016 Oct 27; 2(4): 473-474. doi: 10.3233/BLC-169011. 289. Noyes K, Baak-Kukreja J, Messing EM, Schoeniger L, Galka E, Pan W, Xueya C, Fleming FJ, Monson JR, Mohile SG, Francone T. Surgical Readmissions: results of integrating pre-, peri-, and Postsurgical care. Nurs Open. 2016 May 10; 3(3): 168-178. 290. Messing EM. Beyond Cisplatin-I. Bladder Cancer. 2016 Jul 27; 2(3): 365-367. 291. Rink, M., Crivelli, J. J., Shariat, S. F., Chun, F. K., Messing, E. M., & Soloway, M. S. (2015). Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. European Urology Focus, 1(1), 17-27. doi:10.1016/j.euf.2014.11.001 292. Baack Kukreja, J. E., Kiernan, M., Schempp, B., Siebert, A., Hontar, A., Nelson, B., Dolan, J., Noyes, K., Dozier, A., Ghazi, A., Rashid, H. H., Wu, G. and Messing, EM. Quality Improvement in Cystectomy Care with Enhanced Recovery (QUICCER) study. BJU Int, 2017; 119: 38–49. doi:10.1111/bju.13521 293. Horovitz, D., Feng, C., Messing, E.M. et al. J Robotic Surg (2017).Exraperitoneal vs.

Transperitoneal robot-assisted radical prostatectomy in patients with a history of prior inguinal hernia repair with mesh. https://doi.org/10.1007/s11701-017-0678-0

294. Messing EM. A More Thorough Transurethral Resection. Bladder Cancer (Amsterdam, Netherlands). 2017; 3(1):75-77. doi: 10.3233/BLC-169014.

295. Truong M, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology. The Journal of Urology. 2017; 198(2):316-321. doi: https://doi.org/10.1016/j.juro.2017.01.077.

296. Horovitz David, Feng Changyong, Messing Edward M., and Joseph Jean V. Extraperitoneal vs

Transperitoneal Robot-Assisted Radical Prostatectomy in the Setting of Prior Abdominal or Pelvic Surgery Journal of Endourology. April 2017, 31(4): 366-373. https://doi.org/10.1089/end.2016.0706

297. Truong M, Liang L, Kukreja J, O’Brien J, Jean-Gilles J, Messing E. Cautery artifact understages

urothelial cancer at initial transurethral resection of large bladder tumors. Canadian Urological Association Journal. 2017; 11(5):E203-E206. doi:10.5489/cuaj.4172.

https://doi.org/10.1007/s11701-017-0678-0

https://doi.org/10.1007/s11701-017-0678-0

https://doi.org/10.1089/end.2016.0706

https://doi.org/10.1089/end.2016.0706


298. Blute, M. L., Kucherov, V., Rushmer, T. J., Damodaran, S., Shi, F., Abel, E. J., Jarrard, D. F., Richards, K. A., Messing, E. M. and Downs, T. M. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2) at first transurethral resection of bladder tumor is a significant predictor of subsequent recurrence and progression. BJU Int. 2017; 120(3):387-393 doi:10.1111/bju.13904

299. Messing EM. Re: Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to

Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. European Urology. 201; 722(1):153-154. doi: European Urology.

300. Truong M, Rais-Bahramis S, Nix JW, Messing EM, Miyamoto H, Gordetsky JB. Perineural

Invasion by Prostate Cancer on MR/US Fusion Targeted Biopsy is Associated with Extraprostatic Extension and Early Biochemical Recurrence after Radical Prostatectomy. Human Pathology. 2017; 66:206-211. doi: https://doi.org/10.1016/j.humpath.2017.06.017.

301. Shyr C-R, Chen C-C, Huang C-P, Messing E, Yeh S, Chang C. ASC-J9® increases the

chemotherapy efficacy in bladder cancer possibly via altering NF-kB signals. Molecular Cancer Therapeutics. 2017.

302. Messing EM. The BCG Shortage. Bladder Cancer 2017; 3:227-228. 303. Horovitz D, Meng Y, Joseph JV, Feng C, Wu G, Rashid H, Messing EM. The role of urinary

cytology when diagnostic workup is suspicious for upper tract urothelial carcinoma but tumor biopsy is non-confirmatory. Can Urol Assoc. 2017; 11:E285-E290.

304. Ristau BT, Manola J, Haas NB, Heng DY, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo

RG. Retroperitoneal lymphadenectomy for high-risk non-metastatic renal cell carcinoma: An analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. Journal of Urology 2018; 199(1):53-59.

305. Silvers CR, Miyamoto, H., Messing EM, Netto, G.L., and Lee YF Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer Oncotarget 2017; 8:91199-91208. https://doi.org/10.18632/oncotarget.20043

306. Truong M, Wang B, Gordetsky J, Nix J, Frye T, Messing EM, Thomas J, Feng C, Rais-Bahramis S Multi-institutional Nomogram Predicting Benign Prostate Pathology on MR/US Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy. Cancer 2018; 124; 278-285. https://doi.org/10.1002/cncr.31051

307. Nguyen, H., Welty, C., Lindquist, K., Ngo, V., Gilbert, E., Bengtsson, H, Messing, E. Klein EA, Carroll PR, Paris, P. Pd71-05 Validation Of Gemcap As A Dna Based Biomarker To Predict Prostate Cancer Recurrence After Radical Prostatectomy. The Journal of Urology, 2017. doi:10.1016/j.juro.2017.02.3172

308. Truong M, Frye T, Messing EM, Miyamoto H. Historical and Contemporary Perspectives on Cribriform Morphology in Prostate Cancer. Nature Reviews Urology.2018 doi: 10.1038/s41585-018-0013-1

309. Messing EM, Tangen CM, Lerner SP, et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence SWOG S0337 Randomized Clinical Trial. JAMA. 2018; 319(18):1880–1888. doi:10.1001/jama.2018.4657

https://doi.org/10.18632/oncotarget.20043

https://doi.org/10.18632/oncotarget.20043

https://doi.org/10.1002/cncr.31051


310. Truong M, Feng CY, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, Frye TP. A comprehensive analysis of cribriform morphology on magnetic resonance imaging/ultrasound fusion biopsy correlated with radical prostatectomy specimens. J Urol 2018; 199:106-113.

311. Messing EM. Psychological stress and suicide in bladder cancer patients. Bladder Cancer 2018:245-246.

312. Tao L, Qiu J, Slavin S, Ou Z, Liu Z, Ge J, Zuo L, Guancial EA, Messing EM, Chang C, Yeh S. Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals. Cancer Letter 2018; 430:215-223.

313. Messing EM. Molecular landscape of non-muscle invasive bladder cancer. Bladder Cancer. 2018; 4:131-132.

314. Gurung PMS, Barnett AR, Wilson JS, Hudson J, Ward DG, Messing EM, Bryan RT. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation. Eur Urol Focus. 2020 Jul 15; 6(4):683-697. doi: 10.1016/j.euf.2019.02.012. Epub 2019 Feb 23. PMID: 30803927

315. Wu CH, Silvers CR, Messing EM, Lee YF. Bladder cancer extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of non-malignant cells. http:www.jbc.org/cgi/doi/10.1074/jbc.RA118.006682. Journal Bio Chem 2019; 294(9):3207-3218.

316. Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Predicting renal cancer recurrence: Defining limitations of existing prognostic models with prospective trial based validation. JCO 37:23, 2062-2071.

317. Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA. Evaluation of the UroVysion test to predict recurrence and/or progression of disease after BCG for primary high grade non-muscle invasive bladder cancer: Results from a Prospective Multicenter Trial. Accepted for publication, Journal of Urology, 2019.

318. Kim HL, Mayerson E, Lara PN, Messing E, Tangen C, Shuch BM, Vaishampayan U. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2019 Nov; 5(6):927-929. doi: 10.1016/j.euf.2019.05.006. Epub 2019 May 16. PMID: 31103605; PMCID: PMC6858992.

319. Messing EM. Preventing bladder recurrences after nephroureterectomy for upper track urothelial cancer. Paper Alert. Bladder Cancer 5; 189-191, 2019.

320. Chen J, Chou F, Yeh S, Ou Z, Shyr C, Huang C, Xiang Z, Sun Y, Messing E, Zu X, Chang C. Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling. Oncogene. 2020 Jan; 39(3):574-586. doi: 10.1038/s41388-019-0964-6. Epub 2019 Sep 10. PMID: 31506605.

321. Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2020 Apr; 203(4):684-


689. doi: 10.1097/JU.0000000000000588. Epub 2019 Oct 9. PMID: 31596672; PMCID: PMC7337326.

322. Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA. Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. J Urol. 2019 Nov; 202(5):920-926. doi: 10.1097/JU.0000000000000355. Epub 2019 Oct 9. PMID: 31120373.

323. Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. doi:10.1097/JU.0000000000000588. Epub 2019 Oct 9. PMID: 31596672; PMCID: PMC7337326.

324. Jubber I, Shariat SF, Conroy S, Tan WS, Gordon PC, Lotan Y, Messing EM, Stenzl A, Rhijn BV, Kelly JD, Catto JWF, Cumberbatch MG. Non-visible hematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. Eur Urol. 2020 May; 77(5):583-598. doi: 10.1016/j.eururo.2019.10.010. Epub 2019 Nov 30. PMID: 31791622.

325. Lemke E, Sahasrabudhe D, Guancial E, Bylow K, Johnson S, Messing E, Kilari D. The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? Clin Genitourin Cancer. 2020 Aug; 18(4):e478-e483. doi: 10.1016/j.clgc.2020.01.003. Epub 2020 Jan 27. PMID: 32085986.

326. Messing, Edward. ‘Intravesical Coxsackievirus A21 Therapy for Non-Muscle Invasive Bladder

Cancer’. 28 Mar. 2020: 97 – 98. 327. Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urol Oncol. 2020 Oct; 38(10):796.e1-796.e6. doi: 10.1016/j.urolonc.2020.04.026. Epub 2020 May 17. PMID: 32430255. 328. Messing, Edward M. ‘Arsenic Induced Bladder Cancer’. 11 Jun. 2020: 223 – 224. 329. Messing, Edward M. ‘New Salvage Treatments for Metastatic Bladder Cancer’. 21 Sept. 2020:

399 – 400.

BOOK CHAPTERS

1. Messing EM. Bacterial infections of the urinary tract (female). In: Conn HF, ed. Current Therapy.

Philadelphia, PA: WB Saunders Co; 1983:510-514. 2. Messing EM, deKernion JB. Chemotherapy of bladder cancer. In Wallace DMA, Zingg E, Eds. Bladder

Cancer. Berlin, Germany: Springer-Verlag; 1985:235-262. 3. Messing EM. Interstitial cystitis and related syndromes. In Walsh PC, Gittes RF, Perlmutter AD, Stamey

TA, Eds. Campbell's Urology. Fifth Edition. Philadelphia, PA: WB Saunders Co; 1985; 1070-1094.


4. Messing EM. Tumor antigens in the diagnosis, staging, and prognosis of urologic cancer. In Williams R, Ed. Advances in Urologic Oncology. New York, NY: Macmillan Publishing Co; 1987; 43-68.

5. Richards III WH, Messing EM. Management of retroperitoneal fibrosis. In: Droller MJ, Marshall DK,

Eds. Surgical Management of Urologic Disease - An Anatomic Approach. St. Louis, MO: CV Mosby Co; 1992: 499-507.

6. Messing EM, Richards III WH. Ureteral surgery: anatomical overview. In: Droller MJ, Marshall DK,

Eds. Surgical Management of Urologic Disease - An Anatomic Approach. St. Louis, MO: CV Mosby Co; 1992:465-475.

7. Messing EM. Urethrectomy. In: Fowler J, Ed. Mastery of Surgery: Urologic Surgery. Boston, MA:

Little, Brown and Co; 1992:495-502. 8. Messing EM. Interstitial cystitis and related syndromes. In: Walsh PC, Retik AB, Stamey TA, Vaughan

ED, Eds. Campbell's Urology. Sixth edition. Philadelphia, PA: WB Saunders Co; 1992:982-1005. 9. Messing EM. Genitourinary cancer: prostate, bladder and kidney. In: Brain MC, Carbone PP, eds.

Current Therapy in Hematology-Oncology. Fourth Edition. Philadelphia, PA: BC Decker Inc.; 1992:279-290.

10. Messing EM. Testicular seminoma. In: Resnick MI, Kursh ED, Eds. Current Therapy in Genitourinary Surgery. Second Edition. Philadelphia, PA: BC Decker, Inc.; 1992:168-172.

11. Waples MI, Messing EM. The management of stage T1, grade 3 transitional cell carcinoma of the bladder.

In: Lytton B, ed. Advances in Urology. Vol. 5. St. Louis, MO: Mosby-Yearbook, Inc.; 1992:33-59. 12. Reznikoff CA, Chen X-R, Messing EM. Normal human uroepithelial cell culture. In: Griffiths JB, Doyle

A, Newell DG, Eds. Cell Tissue Culture: Laboratory Procedures. London, England: John Wiley & Sons; 1993.

13. Grose GS, Messing EM. Optimal management of stage D1 prostate cancer. In: Dawson NA, Vogelzang

NJ, eds. Prostate Cancer. New York, NY: Wiley-Liss, Inc.; 1994; 197-213. 14. Bossinger S, Messing EM. Early stage cancers of the prostate, bladder, and kidney. In: Brain MC,

Carbone PP, eds. Current Therapy in Hematology - Oncology. Fifth Edition. Philadelphia, PA: Mosby; 1995; 423-436.

15. Jonler M, Messing EM. Transitional cell carcinomas of the urinary tract: screening, early detection, and

prevention. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, Eds. Comprehensive Textbook of Genitourinary Oncology. Baltimore, MD: Williams and Wilkins Publications; 1995; 351-358.

16. Buzzeo BD, Messing EM. Urothelial cancers of the upper urinary tract. In: McGuire EJ, Bloom D,

Catalona WJ, Lipshultz LI, eds. Advances in Urology, Vol 9. Chicago, IL: Mosby Year Book, Inc.; 1996, 39-74.

17. Messing, EM, Catalona, WJ. Urothelial Tumors of the Urinary Tract in: Walsh, PC, Vaughan Jr, ED,

Retik AB, Wein AJ, eds. Campbell’s Urology. Seventh Edition. Vol. 3 Philadelphia, PA. WB Saunders Co; 1996, 2327-2410.

18. Laitman, CJ, Jonler, M, Messing, EM. The Effects on Men of Prenatal Exposure to Diethylstilbestrol. In:

Larry I. Lipshultz, ed, Stuart Howards, eds. Infertility in the Male, Third Edition. St. Louis, MI. Mosby; 1996, 268-279.


19. Goldstein M, Messing EM. Screening of Bladder Cancer. In: Syrigos K, Skinner D., eds. Bladder Cancer: Biology, Diagnosis and Management. Oxford University Press, London, UK. 1999, 57-70.

20. Oleyourryk G, Messing EM. Screening of Prostate Cancer. In: Syrigos K, ed. Prostate Cancer: Biology,

Diagnosis and Management. Oxford University Press, London, UK. 2001, 71-83. 21. Jung I, Messing EM, Fradet Y. Diagnosis of Bladder Cancer. In: Klein E., ed. Bladder Cancer: Current

Diagnosis and Treatment - in the Series - Current Clinical Urology. Humana Press, Totowa, New Jersey. 2001, 57-83.

22. Jung I, Messing EM. Screening, Early Detection, and Prevention of Bladder Cancer. Chapter 21.

Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology 2nd Edition, Philadelphia, Lippincott Williams & Wilkins, 1999.

23. McNally M, Messing EM. Early Diagnosis and Screening. In: Pagano F, Bassi P, eds. Invasive Bladder

Cancer. Isis Medical Media Limited, Oxford, England. Accepted for Publication 2000. 24. Oleyourryk G, Messing E. Cystitis - Hemorrhagic (Infectious, Noninfectious). In: Gomella L, ed. The 5-

minute Urology Consult. Lippincott, Williams and Wilkins, Philadelphia, PA. 2000, 260-261. 25. Messing, EM. Urothelial Tumors of the Urinary Tract in: Walsh, PC, Vaughan Jr, ED, Retik

AB, Wein AJ, eds. Campbell’s Urology. Eighth Edition. Philadelphia, PA. WB Saunders Co; 2002, 2732-2784.

26. Madeb R, Golijanin D, Messing EM. Early Versus Late Hormone Treatment of Metastatic Prostate Cancer. Evidence Based Urology. Chris Dawson and Gordon Muir, Editors. Castle Hill Barns, Shrewsbury, UK. 2004, 165-180.

27. Messing EM. Urothelial Tumors of the Bladder in: Walsh, PC, Vaughan Jr, ED, Retik

AB, Wein AJ, eds. Campbell’s Urology. Ninth Edition. Philadelphia, PA. WB Saunders Co. 2007. 28. Knopf J, Trivedi D, Messing EM. Bladder Cancer: Epidemiology, risk factors, screening and

chemoprevention. Essentials and Updates in Urologic Oncology, 1st Edition. 2011.

29. Messing EM, Scosyrev E. Epidemiology and Natural History. In: Konety B, Chang S, eds. Bladder Cancer. Springer. 2014.

30. Gaya JM, Palou J, Messing EM. HGT1 Bladder Cancer: Diagnosis and Treatment. In: Lerner S, Sternberg C, Schoenberg M, eds. Bladder Cancer: Diagnosis and Clinical Management. Wiley-Blackwell. 2015.

INVITED EDITORIALS Messing EM. Interstitial Cystitis: A Light at the end of the tunnel. Editorial, J Urol 1999; 161:1797. Mungan NA, Vriesma LJL, Thomas CMG, et al. Urinary bladder cancer test: A new urinary tumor marker in the follow-up of superficial bladder cancer. Editorial Comment, Urology, Accepted for publication, 2001. Fleshner N, Kapusta L, Ezer D, et al. p.53 nuclear accumulation is not associated with prolonged disease-free survival among patients with node-positive transitional cell carcinoma of the bladder. J Urol; 2000:164; 1177-1182, Editorial comment.


Messing, EM. A Structured debate: Immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment. (Editorial) J Urol, 166:508, 2001. Messing EM. Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. European Urol 2007 :( 51); 1139-1143. Messing EM. Node Positive Renal Cell Cancer. Who can be helped? Editorial and Rebuttal. European Urol 2007; 51:1477-1480. Messing EM. Why should we increase public awareness of bladder cancer and how can we do it? Nature Clinical Practice. 2008; 5:117. Mitin T, Blute M, Lee R, Efstathiou J. The role of surgery and radiation therapy in management of lymph node-positive patients with prostate cancer. Oncology; 2013: 27(7); 647-655, Editorial comment.

EDWARD M. MESSING, MD, FACS

Documents

Transcript of EDWARD M. MESSING, MD, FACS